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Cancer immunotherapy involves stimulation of the body’s own immune system to fight cancer. Tumors 
possess myriad suppressive mechanisms that facilitate evasion of the immune system. Immunotherapy 
aims to stimulate immune cells to recognize and attack tumor tissue. While immunostimulatory agents 
have achieved some success in treating cancer, systemic toxicity remains a major concern. In particular, 
systemic exposure to immunostimulants can activate immune cells outside of target tissues, which can 
potentially induce side effects or autoimmune reactions. In the treatment of solid tumors, intratumoral 
(IT) therapy offers unique benefits as an anti-cancer strategy, especially in the ability to bypass obstacles 
of trafficking, tumor penetration, and severe adverse events associated with systemic delivery. IT 
administration of immunostimulants, for example, can work synergistically with checkpoint inhibitors 
making a nonresponsive ‘cold’ tumor ‘hot’ by recruiting and activating tumor infiltrating lymphocytes. 
Unfortunately IT administration does not necessarily preclude the manifestation of systemic adverse 
events; therapy transport out of the tumor and back into systemic circulation can lead to similar adverse 
events as seen with systemic exposure. While many researchers have worked to optimize the efficacy of 
immunostimulants, few have approached delivery design with the consideration of drug retention after IT 
administration. This dissertation sought to explore delivery strategies for two negatively charged 
immunostimulants, polyI:C and CpG, which are potent toll-like receptor 3 (TLR3) and TLR9 agonists, 
respectively. Both compounds exhibit strong induction of interferons, leading to a proinflammatory 
environment after binding to TLRs, thus generating memory and tumor-specific T cells. Both TLR3 and 
TLR9 are located intracellularly; thus negatively-charged polyI:C and CpG macromolecules must be 
internalized by immune cells in order to be efficacious. To achieve both goals of increased retention and 
intracellular delivery, polycations were selected as a delivery tool. Polycations have historically been 
employed for intracellular delivery of nucleic acid material. This dissertation suggests that electrostatics 
can aid in injection site retention through interactions with highly negatively charged extracellular matrix. 
In chapter 2, polylysine, at a range of molecular weights, was evaluated for its ability to complex with 
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immunostimulants and subsequently activate TLR(s). Chapter 3 presented a novel idea utilizing 
Glatiramer Acetate (GA), better known as Copaxone® as a delivery tool for immunostimulants. GA is a 
highly positively-charged polypeptide and is currently an FDA-approved therapy for multiple sclerosis. In 
this work, we generated small nanoparticles known as polyplexes, which form when mixing positively-
charged GA and negatively-charged immunostimulant(s) (polyI:C or CpG). Together from chapters 2 and 
3, we found that the relationship between complexation and TLR activation depends on the strength of the 
interaction in the polyplex. In a tumor model of head and neck squamous cell carcinoma, GA polyplexes 
were able to decrease tumor burden as compared to the vehicle controls. Therefore, this dissertation 
demonstrates that using polycations to complex with immunostimulant(s) is a promising approach to 
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Chapter 1: 
Intratumoral Delivery of 
Cancer Therapeutics: 
Biophysical Considerations for 
Therapies in Clinical Trials 
1
1. Introduction
Recent clinical successes of intratumoral (IT) therapy have stimulated a wave of new clinical trials 
investigating IT therapies both alone, and in tandem with other immuno-oncology agents. IT therapy offers 
unique benefits as an anti-cancer strategy, especially in the ability to bypass obstacles of trafficking and 
tumor penetration.1 Severe adverse events associated with systemic delivery of cancer immunotherapies2-3 
can be avoided by delivering small doses IT.4 IT administration of immunostimulants, for example, can 
work synergistically with checkpoint inhibitors making a nonresponsive ‘cold’ tumor ‘hot’ or by recruiting 
and activating tumor infiltrating lymphocytes.4-6 Intuitively, the design of IT therapies is significantly 
different than that of systemic cancer medications, as these localized interventions aim for retention at the 
administration site or draining lymph nodes with limited systemic exposure. In this review, we highlight 
transport mechanisms involved in IT delivery and recent clinical trials while elucidating relationships 
between biophysical characteristics of the formulation with efficacy.  
1.1 A Brief History of IT Therapy 
Merck’s acquisition of Immune Design sparked a new wave of activity around the already building 
tide of IT therapy. Leading up to its acquisition, Immune Design had disclosed two IT immunotherapies, 
G100 and ZVEC-IL12.7-8 G100 is a stable oil-in-water emulsion containing glucopyranosyl lipid A (GLA), 
a potent toll-like receptor 4 (TLR4) agonist that induces activation of local dendritic cells (DCs) to elicit 
broad, patient-specific anti-tumor immune responses.8 Notably and importantly for the broad consideration 
of IT immunotherapies, G100 exhibited abscopal effects - the shrinkage of even non-injected tumors.9 This 
highly promising therapy received orphan drug designation by the U.S. Food and Drug Administration 
(FDA) and European Medicines Agency (EMA) for follicular non-Hodgkin’s lymphoma, further 
highlighting IT interventions as a compelling therapeutic approach.10 Moving forward, G100’s efficacy was 
even more pronounced when applied in combination with Merck’s anti-PD1 checkpoint inhibitor, 
Keytruda, alongside radiation therapy.8  
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The first successful IT cancer therapy was performed over 100 years ago by Dr. William Coley on 
patients with inoperable solid tumors. Coley noticed a patient with an inoperable egg-sized sarcoma on the 
face was completely cured after suffering a severe infection from a failed skin graft. He proposed that by 
introducing a bacterial infection at the site of the patient’s tumor, an immune response against the tumor 
might be generated. This intervention proved an unprecedented success, and Coley went on to treat many 
more patients with bacterial-derived heat-killed toxins. Coley’s Toxins became one of the first examples of 
cancer immunotherapy.11-12 With the introduction of radiation and chemotherapy, Coley’s toxins largely 
faded into the background and are no longer in use. Since Coley’s seminal work, very few IT cancer 
therapies have been approved in humans, but many have been investigated in clinical trials.  
Among the few IT therapies available today, the Bacillus Calmette-Guerin (BCG) instilled 
transurethral for patients with bladder cancer can be considered an IT therapy of sorts, which applies the 
very same concepts first laid out by Coley. First used nearly 40 years ago, no other treatment for bladder 
cancer has surpassed the success of BCG treatment.13 Imiquimod, a TLR7 agonist, is the only other FDA-
approved IT therapy for cancer. Imiquimod is topically applied to genital warts or basal cell carcinomas14. 
Today, there are many more agents being investigated for IT delivery that exploit the immune system, 
including pathogen associated molecular patterns (PAMPs), monoclonal antibodies (mAbs), cytokines, 
small molecules, viral and gene therapies, and autologous cells.15 
Despite scientific advances in the field of oncology, generally, cancer mortality rates have 
decreased only marginally over the past three decades.16 The major persisting barriers for effectiveness and 
toxicity in cancer immunotherapies stem from delivery and transport constraints, as well as off-target 
adverse events. Systemically delivered therapeutics encounter countless obstacles on their journeys to 
tumor tissue that lead to a very small fraction of the compound reaching the tumor while much of it remains 
in circulation throughout healthy tissues.17 Reaching the tumor alone is not a sufficient criterion for dictating 
efficacy with a therapeutic agent. The drug must penetrate the tumor where it will ultimately encounter the 
TME, which often differs drastically from healthy tissue. While IT administration of therapeutic agents can 
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overcome some of the concerns of systemic delivery, we must consider the TME and its potential retention, 
clearance, and modification mechanisms.  
1.2 Tumor Microenvironment 
The TME is heterogeneous between patients, tumor types, and often even within individual tumors, 
making generalities about transport difficult to ascertain. Overall, tumor tissue is physically distinct from 
normal tissue in that it has poorly organized vasculature with inconsistent vessel diameters and more 
prevalent branching.18 Further, tumor cell distance from blood vessels results in restriction of oxygen supply 
and hypoxia in portions of the tumor.19 This roughly organized vasculature and hypoxic setting creates a 
microenvironment with increased fluid leakage and elevated interstitial fluid pressure (IFP). These 
conditions support decreased uptake of therapeutic molecules, which is correlated with poor prognosis in 
some cases.20 The lack of proper vasculature for gas exchange and delivering nutrients leads to areas of 
hypoxia within a tumor.21-22  
When delivering a drug systemically, distribution to all cells in a tumor is dependent on the distance 
between vascular beds. The compound may have to penetrate a tumor up to 200 µm to reach all of its 
targeted cells.23 Moreover and compared to the extravascular space in healthy tissue, tumors tend to have 
higher extracellular matrix density lacking functional lymphatic vessels. This dense network causes 
increased interstitial fluid pressure which further limits interstitial diffusion and the drainage of fluid from 
the tissue.20, 24 Together, dense but leaky vasculature and limited lymphatic drainage may contribute to 
enhanced permeability and retention of tumor tissue, however, this phenomena has not been fully supported 
in human tumors.25-26 These conditions can decrease uptake of circulating therapeutic molecules, which is 
correlated with poor prognoses in some cases.20 
While intracellular pH in tumors and normal tissue is similar, extracellular pH can be more acidic 
in tumors.27 Increased extracellular acidity and anerobic glycolysis alters the pH gradients found in the 
TME versus healthy tissue.27-28 Evidence suggests that higher acidity may increase tumor cell invasion and 
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metastatic potential while also aiding evasion of immune surveillance.29-30 For drugs that rely on ionization-
dependent diffusion, the extracellular pH may cause the drug to become charged, preventing diffusion 
across membranes.25, 27  
Tumor tissue contains myriad immune-suppressive signals and mechanisms that allow malignant 
cells to proliferate undetected by the immune system. T-regulatory cells are attracted to the tumor by 
chemokines and aid in suppressing antigen presenting cells (APCs) that may otherwise stimulate a response 
against tumor antigens.31 Additionally, tumor cells can secrete anti-inflammatory and regulatory cytokines 
that facilitate cancer growth and directly prevent dendritic cell (DC) activation.  Tumor cells can also limit 
the expression of co-stimulatory molecules (MHC II, CD80, CD86), potentially inducing anergy or 
senescence in infiltrating T cells.31-32 At the other extreme, overstimulation can cause T cell exhaustion 
from chronic exposure to tumor antigen.33 Finally, tumor cells can also downregulate the expression of 
tumor antigen over time, evading recognition by cytotoxic T-lymphocytes (CTLs). Cytotoxic T lymphocyte 
antigen 4 (CTLA-4) and programmed death ligand 1 (PD-L1) pathways are both exploited by tumors. While 
engaging different mechanisms, both induce immunosuppressive signals through cytokines that reduce 
proliferation or cause apoptosis of T-cells.  
5
Figure 1. Concept of intratumoral (IT) immunotherapy with an abscopal effect. Injection with 
immunotherapy can activate an innate immune response leading to systemic effects due to circulating 
immune cells.   
1.3 Overcoming the TME (Immune mechanism of immunostimulants)  
Traditional cancer treatments like chemotherapy and radiation aim to directly kill tumor cells and 
the mechanism of action is not directly limited by the TME.  On the other hand, clinical studies indicate the 
suppressive environment within the tumor can be overcome by immunostimulants. Immune cells can be 
activated by immunostimulants in the presence of tumor antigen, traffic to lymph nodes, and then create 
tumor antigen specific T cells via cross presentation (Figure 1). These antigen-specific T cells can then 
circulate back to the tumor or to distal tumors and instigate tumor cell killing. The activation of the innate 
immune response creates a pro-inflammatory environment and can result in recruitment additional immune 
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cells to the tumor. Some of the actives used in cancer therapy that will be reviewed in this article are listed 
in Table 1.  
Table 1. Strategies to treat cancer. 





• Binding toll-like receptors (TLRs), RIG-I-like receptors
(RLRs), NOD-like receptors (NLRs), and cell
membrane components





Cytokines • Binding to specific cell-surface glycoproteins
• Downstream signaling leading to innate immune
response 





• Interaction of viral surface proteins with cell surface
proteins
• Target cancer cells by exploiting pathways, receptors,
and mechanisms that promote tumor growth
• Viruses can be used to infect cancer cells or as
vehicles for gene delivery







• Binding to specific protein on surface of tumor or
immune cell
• Checkpoint blockades inhibit immune suppression





Small Molecules • Extra and Intracellular targets, must diffuse or
transport through cell membrane
• Cytotoxins → Cause damage to various cell functions
• Targeted drugs → disruption of specific pathways





1.4 Intratumoral Transport 
Identifying and targeting dysregulated immune mechanisms within the TME is key, but an 
understanding of transport in the TME is also crucial for the design of IT cancer therapies. With IT injection, 
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transport considerations can be simplified to the major themes of molecular transport within the TME, 
exfiltration from the TME, cellular uptake, and binding to intra- and extra- cellular proteins (Figure 2). IT 
transport mechanisms are influenced by various factors that affect the retention or transport out of the tumor 
of the anti-cancer therapy (Table 2).  
Transport of molecules through normal extracellular matrix is based on both diffusion along a 
concentration gradient as well as advective convection (or bulk transport of mass) along a pressure 
gradient.18 Conversely in the TME, transport of anti-cancer agents after intratumoral administration are 
governed by diffusion, as elevated IFP makes the bulk IT pressure gradient negligible.40-41 Close to blood 
vessels, however, where IFP can exceed that of the vascular fluid, a gradient is created and intravasation of 
the therapeutic agent out of the tumor can occur by diffusion and advective transport.  
Though the blood vessels represent an escape route for the therapeutic agent, the abnormal and 
poorly organized vascular architecture characteristic of the TME increases retention at the tumor cells that 
are distant from the vessels, as compared to normal tissue.42 The absence of lymphatics in the TME 
increases IFP and reduces the elimination or drainage of the agent before its anti-cancer action, improving 
IT retention.43-44 Despite the relatively ineffective lymphatic drainage in the TME, it still represents the 
major route for metastasis and a route of escape for the IT therapeutic.45 Therefore, angiogenesis, which 
seeks to normalize tumor vasculature leading to increased blood flow and reduced IFP, can result in a 
decrease in retention time when enhanced within the tumor.46-48 Vascular permeability could have a 
negative effect on tumor retention time if encumbered, but this characteristic is insignificant in most tumors 
because blood vessel fenestrations are present and confound its effects.49-50  
Densely packed collagen fibers are characteristic of the TME, and they pose transport resistance, 
which results in an increase in intratumoral retention.18, 51 Fibrillar collagen and high IFP, among other 
TME characteristics, contribute to a high mechanical solid stress in the tumor.52 This stress results in an 
effect on retention similar to that of IFP.  Cellular packing density is also a relevant factor; loosely packed 
tumor cells enable fast, thorough penetration by the therapeutic agent, increasing retention at tumor.53 
However, the inverse can be the case where densely packed cells decrease drug retention as well. Finally, 
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cellular uptake or binding of the therapy can occur by passive diffusion, active transport, or other 
mechanisms depending on molecular properties.  
Drug features such as molecular size, charge, and other properties (Table 2) influence intratumoral 
residence time. Water soluble molecules diffuse more easily in the TME resulting in a lower retention in 
the tumor,54 but increases in hydrodynamic radius can reverse these effects. It is critical to balance size such 
that a therapeutic or its carrier is small enough to diffuse through the TME while avoiding clearance through 
lymphatic drainage.55 Drug diffusion and retention deep inside the tumor mass is largely affected not only 
by the molecular size but also binding kinetics and affinity.54 Molecular charge may also be exploited such 
that the acidic extracellular pH in the tumor has a positive impact on the retention. The plethora of factors 
that influence TME transport offer unique opportunities for the targeted delivery and retention of drugs in 
the IT space such that the exploitation of these abnormalities can be harnessed to maximize therapeutic 
effect.  
 
Table 2. Factors affecting transport of therapy out of the tumor after intratumoral injection. 
 
 
Microvascular permeability Decreases retention at tumor, but insignificant where blood vessel fenestration is present
Abnormal vascular architecture Increases retention at the tumor
Absence of lymphatics Increases retention at the tumor
Interstitial fluid pressure (IFP) Increased IFP increases retention time at the tumor but decreases it close to vessels
Solid stress elevation Increases retention within the tumor, but decreases the retention close to vessels
Angiogenesis Decreases retention at the tumor
Concentration gradient Increases diffusion out of tumor, decreasing retention
Water solubility Water soluble agents diffuse easily in the TME, decreasing retention in tumor 
Extracellular pH Effect on retention at tumor depends on the carcinogenic agent's molecular properties (pI, pKa)
Fibrillar collagen Increases retention at tumor
Cellular packing density Low packing density increases retention at tumor
Physicochemical factors Phenomena
Tumor tissue factors Phenomena
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Figure 2. Representative transport and kinetic processes in intratumoral injection therapies. The 
therapeutic agent can diffuse through the TME, enter the cell, be bound by extracellular or 
intracellular proteins, unbind them, or leave the tumor into blood vessels, lymphatics, peripheral 
blood or adjacent tissue by diffusion and advective convection. Diffusional transport the agent 
back into the tumor is expected to be minimal.  
2. Current Cancer Therapies 
2.1 Radiation 
Radiation therapy employs highly focused energy to kill or damage tumor cells.56-58 It works by 
damaging the DNA of tumor cells to prevent their proliferation and cause cells to die. The goal of radiation 
therapy is to direct waves to cancer cells while limiting exposure to normal cells. Radiation therapy can be 
used to treat tumors alone, but it is also employed in combination with other cancer treatments, such as 
chemotherapy, immunotherapy, and surgery.57-59 For instance, radiation can be used to shrink the tumor 
before surgery or to eliminate residual tumor cells post-surgery. Radiation therapy can be local, externally 
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or internally, where the radiation source is from an external machine or from a radioactive source placed at 
or near the tumor. Contrastingly, systemic radiation therapy involves taking a radioactive drug taken orally 
or IV, allowing the drug to be distributed throughout the body and target towards tumor cells. The type of 
radiation therapy given to patients may depend on a variety of factors, including the type of cancer, the size 
of the tumor, and the proximity of the tumor to radiation sensitive normal tissues. Despite efforts to 
minimize radiation damage to non-cancerous normal tissues, damage to normal tissues is inevitable, leading 
to side effects such as fatigue, hair loss, and skin irritation.  
2.2 Chemotherapy 
Cancer therapy was dominated by surgery and radiation until the 1960s when a plateau in survival 
rates for advanced cancers was finally overcome with the addition of chemotherapeutical drugs with these 
treatments. Chemotherapies are cytotoxic anti-cancer agents that target quickly proliferating cells non-
selectively; both normal and cancer cells are subject to their mechanism of action.60 These agents can be 
classified according to their many varied cytotoxic mechanism as alkylating agents, platinum compounds, 
antimetabolites, anthracyclines, topoisomerase inhibitors, tubulin-binding drugs, and tyrosine kinase 
inhibitors. 
The administration routes for chemotherapy include intravenous, intramuscular and oral. The most 
common route of administration is intravenous, given the fact that most chemotherapeutic drugs exhibit 
poor oral bioavailability. Chemotherapy drugs undergo metabolism in the liver followed by excretion via 
the kidney or bile, but the metabolism differs among patients, mostly due to genetics. Patients with faster 
metabolisms may process and excrete the agents too rapidly to benefit from therapeutic effects, while those 
with slow metabolism have an excessive amount of drug reach their bloodstream, which makes them suffer 
the side effects more.61 All chemotherapy patients, however, will suffer from some degree of consequences 
from systemically administered, non-selective cytotoxic action. 
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2.3 Immunotherapy 
Cancer immunotherapy stems from Coley’s seminal work and harnesses the body’s own immune 
mechanisms to fight cancer.  Though the first immunotherapies can be traced back over a century ago, it is 
only in the last decade that scientists have made significant progress in creating immunogenic cancer 
therapeutics as alternatives to traditional treatments like chemotherapy and radiation. Today, several 
therapies have been approved to treat broad types of cancer.62 The major classes of immunotherapies 
include checkpoint inhibitors, oncolytic viruses, cell-based immunotherapies, cytokines and adjuvants.63-64 
Immune checkpoint inhibitors block the checkpoint receptors to prevent tumor cells from escaping immune 
system attacks, resulting in enhanced anti-tumor responses. Ipilimumab (Yervoy®), an antibody against 
cytotoxic T-lymphocyte antigen-4 (CTLA-4), is the first approved and most notable immune checkpoint 
inhibitor that significantly increased the survival of metastatic melanoma patients.65-66 Other major 
inhibitors include the antibodies of programmed cell death protein-1 (PD-1) (e.g. Keytruda) or its ligand 
(PD-L1) (e.g. Imfiazi).66 However, the use of these inhibitors are commonly associated with immune-
related adverse events (irAEs) and toxicities as a consequence of over activation of T-lymphocytes.67 
Oncolytic viruses (OVs) fight cancer by both infecting the cancer cells and stimulating anti-tumor immune 
responses, and can be engineered with optimized tumor selectivity. The oncolytic herpesvirus talimogene 
laherparepvec (T-Vec) is the first approved OV for the treatment of advanced melanoma, but its toxic side 
effects caused by genetic manipulation still remain a safety concern.68 Cytokines, often combined with the 
use of adjuvants to boost the efficacy, are immunomodulators that enhance the host anti-tumor immune 
responses. Interferon-α and interleukin-2 are two types of cytokines that have been approved for the 
treatment of several types of leukemia and melanoma.69 Anther branch of immunotherapy includes 
adjuvants, which are substances that mimic the natural microbial ligands and are added to vaccines to 
improve immunogenicity. Cervarix, an approved vaccine for human papillomavirus (HPV) contains an 
adjuvant called AS04 that includes a TLR4 agonist-based system.70  
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Cellular immunotherapies, including adoptive cell transfer, enhance the tumor antigen presentation 
to the immune cells and improves the efficiency to target or kill tumor cells. One form of this rapidly 
emerging immunotherapy called chimeric antigen receptor T (CAR-T) therapy involves autologous T cells 
engineered to be specific for antigens expressed on the tumor. Typically, this therapy also requires a pre-
conditioning treatment of lymphodepletion prior to infusion of the cells for increased T cell expansion. The 
first CAR-T cell therapy, Kymriah was approved by the FDA less than two years ago, in 2017 for the 
treatment of B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in the second or later 
relapse. Kymriah, or tisagenleceucel, is a CD19 directed autologous T cell containing co-stimulation zone 
4-1BB (CD137). The second and only other approved CAR-T cell therapy, Yescarta (axicabtagene 
ciloleucel) was approved by the FDA only a few months after Kymriah. Yescarta is also a CD19 directed 
CAR-T cell but differs structurally from Kymriah. Yescarta is approved for use in adults with relapsed or 
refractory diffuse large B-cell lymphoma (DLBCL). While CAR-T cell therapy dominates the adoptive 
transfer cancer immunotherapy another therapy called Provenge or sipuleucel-T was the first cancer vaccine 
to be FDA approved. Provenge is comprised of autologous T cells selective for prostate acid phosphatase 
(PAP) that is expressed in 95% of prostate cancers.71-72 The most common adverse reactions to Provenge 
include fever, and fatigue. Provenge, interestingly, does not seem to cause CRS as CAR-T cell therapies 
do. For all these T–cell-based therapies, insufficient cell trafficking, tumor microenvironment, inhibitory 
cytokines, and regulatory T-cells are still obstacles for the efficacy of the therapies.73  
Together, the explosion of immunotherapeutic breakthroughs illustrates the immense promise of 
using the immune system to fight cancer, but each of the examples carry substantial risks as a consequence 
of systemic exposure. Adjuvants and TLR agonists can trigger intense immune anaphylaxis that resembles 
that of sepsis. CAR-T technologies have been extensively reported to leave patients susceptible to off-target 
toxicities. These unmitigated dangers highlight the importance of new strategies for treating cancer that can 
act in safer, more specific fashion. Leveraging the TME through IT administration is one such compelling 
approach to this problem, and in this review we will assess the state of these developing technologies. 
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3.  IT Therapies in Clinical Trials 
Traditional cancer research has focused on the development of cytotoxic drugs that target cancerous 
cells with higher degrees of specificity. Today, many approaches are seeking to harness the power of the 
immune system to stimulate anti-tumor responses. Particularly with IT immunotherapy, the aim is to 
employ the tumor as its own vaccine.4 A major benefit of IT immunotherapy is the potential to achieve an 
abscopal response due to generation of circulating anti-tumor immune cells figure 1.  While many types of 
IT therapies are in progress for clinical trials, we will mainly discuss trials with posted or published data 
and we will only briefly consider the clinical therapies yet to produce results. Highlights of recent and 
upcoming clinical trials of IT therapies are reflected in table 3.  
3.1 Pathogen-Associated Molecular Patterns 
Pathogen-Associated Molecular Patterns (PAMPs) are non-self molecules that inherently activate 
innate immune responses. PAMPs are recognized by pattern recognition receptors (PRRs) including toll-
like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors, RIG-I-like 
receptors (RLR), stimulator of interferon genes (STING) receptors, and C-type lectin receptors (CLR).74 
For example, motifs from bacterial infection can be detected and swiftly acted against when unmethylated 
CpG DNA binds to TLR9 on the endosomal membrane of cells to induce immune activation.75-76 Multiple 
CpG structures have been developed to ligate this pathway, and many elicit different (albeit robust) immune 
responses.  Some approaches have multimerized CpG or even modified it as closed loops in favor of 
increased stability and efficacy.5, 77-78 Derivatives of lipopolysaccharide (LPS) sourced from gram negative 
bacteria are another class of PAMP that stimulates an immunity through binding TLR4 on the outer cell 
membrane.8 Several other agonizing pathways are under investigation in cancer immunotherapy including 
mimics of pathogen infection, RNA or DNA, which bind to TLR3, TLR7/8, RIG-I receptors, or STING 
receptors.4, 74 Finally, attenuated bacteria itself has been explored in IT immunotherapy; intravesicalar BCG 
for bladder cancer is one of the few “intratumoral” immunotherapies that is currently FDA approved.79 
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PAMP immunotherapies are some of the first developed for IT administration. However, since these motifs 
are formulated to mimic components of bacterial and viral pathogens (which the human body is primed to 
elicit efficient and robust immunity against), many of these candidates pose a high probability for 
significant adverse events (AEs) when these PAMPs are able to leak into systemic circulation. For example, 
several trials investigating SD-101, a CpG oligodeoxynucleotide, in combination with other anti-cancer 
modalities have resulted in a 100% AE rate that includes detriments seen in authentic pathogen infections 
such as sepsis. It seems that PAMPs alone act as a major driver of AEs (as opposed to combination therapy 
implements); one trial studying G100, a synthetic TLR4 agonist, led to an AE incidence greater than 80%.  
3.1.1 Tumor Retention Mechanism of PAMPs 
The mechanism of PAMPs is dependent on receptor binding which triggers downstream signaling 
cascades to promote innate immune responses. Receptors for PAMPs are located on both extra- and 
intracellular membranes of immune cells (depending on the mechanism). An ideal IT therapy incorporating 
PAMPs should both be formulated to target these receptors and retain at the injection site. While IT 
administration can reduce the side effects associated with systemic administration, immunostimulatory 
molecules can still leak out of the tumor and cause AEs as if they were injected systemically.  
Unmethylated CpG oligonucleotides are PAMPs that mimic bacterial DNA and trigger an innate 
immune response upon binding to TLR9. PF-3512676 is a class B, linear CpG formulated as a sodium salt 
with a molar mass of 8204 g/mol.80 The formulation of PF-3512676 is proprietary, however, we presume it 
is un-modifed, water-soluble, negatively charged, and does not form higher order structures.81 Clinical trial 
results are promising with IT administration in B-cell lymphoma and mycosis fungoides but interestingly a 
higher percentage of AEs were experienced in mycosis fungoides patients receiving the same dose.82 The 
differences between the AEs could be a result of therapy retention diversity due to the extreme heterogeneity 
in vasculature of tumors across different types and locations. In a phase 2 study with lymphoma patients, 
an increased dose resulted in similar efficacy but more than doubled the percentage of AEs, likely a result 
of increased systemic exposure.83 Another presumably unmodified and soluble CpG therapy, SD-101, is a 
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class C CpG. While the structural and formulation information is proprietary, CpG class C is known to form 
dimers. In IT trials, SD-101 exhibited promising abscopal effects, however, there were 100% grade 1-2 
AEs, and a high incidence of AEs at grade 3 or above including some severe AEs (SAEs).  
Many approaches have utilized structurally modified CpG ODNs to increase immunogenicity and 
stability. IMO-2125 exploits an interesting design in its two strands of class C CpG linked at the 3’ end 
consisting of an 11-mer of CpG on each flanking end to allow formation of intermolecular structure that 
deters intramolecular interaction.78, 84 Favorable potency may be retained by the exposed 5’ ends which are 
pertinent for CpG’s binding mechanism.76, 84 This variant is formulated as a sodium salt with a molecular 
weight of 7712 g/mol and likely forms dimers.76, 85 IMO-2125 has been granted fast track designation and 
orphan drug designation by the FDA and has shown promising results in early trials with fewer AEs than 
other most other IT TLR agonists. Additionally, this modified CpG therapy reaps increased TLR9 activation 
over unmodified CpG likely due to increased metabolic stability from the chemical linkage of the 3’ ends.84  
Another consideration for CpG based therapies is the type of backbone. In nature, CpG has a 
phosphorodiester (PO) backbone, however, synthetic CpG is often made with a phosphorothioate (PT) 
backbone to increase its stability in vivo to enhance potency.86 The creators of MGN1703 purport that the 
PT backbone is to blame for toxic side effects seen when injecting this variant of CpG, however.87 They 
developed a covalently-closed loop of CpG with its native PO backbone in attempts to avoid PT-associated 
toxicity and enhance the stability that hinders the use of native PO. Similarly, CMP-001 is a CpG class A 
with the native PO backbone that is modified to assemble into quarduplexes.5, 76 Clinical results for both of 
these compounds are pending, and they may provide an interesting precedent for future trials employing 
modified and native backbones of CpG.  
One method to boost potency by increasing intracellular PAMP delivery is formulation with a 
polycationic carrier. PAMPs whose receptors are intracellular (like TLR9, TLR3, and RIG-I) may benefit 
from a cationic carrier or particulate formulation for attraction to cell surfaces and increased APC uptake, 
respectively. Two such TLR3 agonist candidates, Hiltonol and BO-112, include polyI:C formulated with 
polycations for improved intracellular delivery potential. This strategy may also increase retention at the 
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injection site and minimize systemic exposure due to increased size and electrostatic interactions at the site 
of injection. In the most recent update of an IT BO-112 clinical trial, patients exhibited only mediocre 
overall response rate (ORR) and high percentage of AEs, however, patients saw increase in immune 
circulating cells and no BO-112 was detected in the blood post injection indicating injection site retention.88 
According to a patent describing its formulation, BO-112 is an aqueous composition at pH 2.7-3.4 with 
glucose or mannitol in an optimal particle size range of 45-85 nm and zeta potential between 40-45 mV.89 
Optimal size of particles for APC uptake and processing is estimated to be ~100 nm, similar to that of 
authentic viruses.90 The N/P ratio for the polyI:C/PEI complex is between 2.5-4.5 and the PEI MW is 
between 17.5-22.6 kDa.89 IT Hiltonol (polyI:C:LC) showed preliminary success in a single patient on both 
local and distal tumor sites however systemic side effects or AEs were not reported.91 Hiltonol is formulated 
with carboxymethylcellulose (CMC), a hydrophilic, negatively charged material, in an aqueous saline 
solution. The molar ratio of PO4 groups to the ε amino group of the lysine in polyIC:LC is 1:1 which 
corresponds to an excess of ε amino groups which may contribute to further complexing with CMC.92 The 
polylysine used ranges from 13-35 kDa.92 As intracellular delivery is critical for agonists with 
intracellularly located TLRs, formulation with a polycation addresses the attraction to cell surfaces and aids 
in tumor retention.  
RIG-I agonist candidate, MK-4621 is a synthetic RNA oligonucleotide that alone caused 100% 
grade 1-2 AEs and 48% grade 3-4 AEs in a (terminated) IT clinical trial in solid tumors.93 Upcoming trials 
plan to use a complex of MK-4621 with a PEI variant (JetPEI).94 It will be interesting to learn whether the 
complexation of negatively charged RNA with positively charged JetPEI will increase retention and 
intracellular delivery while decreasing systemic toxicity or AEs in comparison to uncomplexed MK-4621. 
Another strategy for improving efficacy and retention is formulation into an emulsion. An 
optimized TLR4 agonist, G100 is a glucopyranosyl Lipid A (GLA) derivative with a single phosphate group 
and six C14 acyl chains formulated in a squalene emulsion.95 The emulsion contains the excipients squalene, 
egg phosphatidyl choline (PC), DL-α-tocopherol, and Poloxamer 188.96 The particle/droplet size has been 
reported to be 82.7- 111 nm95-98 and zeta potential measurements -17 mV.90 Because TLR4 is located on 
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the surface of the cell, intracellular uptake is not necessary for the mechanism of a TLR4 agonist. Rather, 
formulation efforts should focus on accessibility of the agonist as well as drug release, and local retention. 
For lipid emulsions, retention in tumor tissue is optimal for cationic materials, and in a size range of 120-
250 nm.99-100 Research has indicated that the formulation of GLA has critical effects on TLR activation and 
that in vitro data does not translate well to in vivo results.98 GLA-SE (G100) resulted in greater immune 
activation than GLA formulated as an aqueous nanosuspension in various mouse models as well a human 
skin explant model.98 Efficacy of GLA itself could be highly dependent on GLA density within a particle 
or droplet which is dictated by formulation and would need to be optimized in humans. 
A more rudimentary approach to immunotherapy is the use of live attenuated bacteria. IT 
Clostridium novyi-NT trials are in progress but too early on to draw comparisons.101 IT BCG resulted in no 
better than stable disease and all patients experienced AEs or SAEs. BCG is a gram positive, rod shaped 
bacterium. In the case of the TICE BCG vaccine, the average length of the bacterium is 2.36 µm and a 
width of 0.474 µm but there is evidence of micro-aggregates approximately 30-50 nm in diameter.102 BCG 
are negatively charged but can be positively charged at lower pH’s as the pI depends on the method of 
preparation.102 BCG is recognized by TLR4 and TLR2 through its mycobacterial components like cell wall 
skeleton and peptidoglycan but also TLR9 through its bacterial DNA.103 More research is needed to evaluate 
transport of bacterial candidates after IT injection.  
Overall, it is apparent that unmodified TLR agonists lead to a greater AE incidence than those 
structurally modified or formulated with a cationic carrier. For example, research by Lynn et. al. studied 
TLR 7/8 agonists attached to polymer scaffolds in a variety of structures and concluded that particle 
formation was critical for improved local retention and innate activation.104 TLR agonists comprised of 
DNA or RNA motifs are naturally negatively charged. Since extracellular space and cell membranes are 
also negatively charged, IT administration of these compounds is not conducive to retention. While the 
rationale for formulating with a cationic carrier has historically been to aid in cell penetration for 
intracellular TLR delivery, it is likely that net positively charged formulations could further benefit from 
retention through electrostatic interactions at the injection site. Such interactions could feasibly limit 
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systemic exposure and mitigate the AEs commonly associated with PAMP immunotherapies. Further 
exploration of the optimal physiochemical properties for retention and efficacy would be vital for the 
research of future IT therapies incorporating PAMPs. 
3.2 Cytokines 
Cytokines play an important role in cell signaling and are major regulators of immunity. Therefore, 
these immunological signals have drawn interest for their immunostimulatory function to potentially 
activate immune system and encourage the destruction of cancer cells.105-106 Several types of cytokines have 
been investigated as immunotherapies (table 3). Granulocyte-Macrophage Colony Stimulating Factor 
(GM-CSF) is a growth factor that stimulates hematopoietic stem cells to differentiate into dendritic cells, 
granulocytes, and monocytes – cells capable of potentiating robust immune responses through antigen 
processing and presentation.107 GM-CSF is a prominent stimulatory agent being used to promote the 
activation, maturation, and migration of immune cells to collectively elicit anti-tumor action. Where results 
are posted, trials administering GM-CSF exhibited AEs lower than 15% with tumor size reduction rates 
exceeding 85%. 
IL-2 is a cytokine with an alternate immunostimulatory mechanism that has also been widely 
explored in cancer. IL-2 activates cytotoxic effector cells and causes them to proliferate.108 The T cell 
expansion that ensues in the presence of IL-2 has the potential to promote an anti-tumor response that 
overcomes the senescent microenvironment typically established by tumors.109 IL-2 does not seem to be as 
safe as GM-CSF; trials commonly report systemic AEs in greater than 50% of patients. However, one Phase 
2 trial exploring Proleukin (intratumoral IL-2) exhibited an 85% complete remission (CR) rate in tumor 
metastases, suggesting high potential for the efficacy of this T cell-stimulating signal when directed to the 
tumor microenvironment. 
Intratumoral cytokine immunotherapies extend far beyond GM-CSF and IL-2 regimens alone. 
Recombinant alpha-interferon has been administered intralesionally in patients with prostate cancer to 
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achieve a 30% CR rate.110 Tumor Necrosis Factor-α (TNFα) has been intratumorally injected while co-
administering subcutaneous IFN-a2b for advanced prostate cancer as well. Notably, TNFα leakage into the 
systemic circulation was observed after just 2 hours of injections, and this leakage may have contributed to 
AEs. Systemic exposure with IT cytokines is intuitively common, as these proteins are largely soluble and 
small (<70 kDa).111 Recombinant human interleukin‐12 (rhIL‐12) in six head and neck squamous cell 
carcinoma (HNSCC) was detected in the plasma 30 minutes after the IT injection with a half-life of 7.2 
h.112 Such systemic exposure is troubling, as a phase 2 study that used a similar treatment regimen on 10 
patients HNSCC resulted in high toxicities.113 
Cytokines elicit signaling cascades by acting in step with other directive signals, so cocktail 
approaches and combination therapies have also been attempted, but with limited success. One study 
investigated a multikine solution (combination of natural interleukins) that was injected IT or peritumorally 
in patients with HNSCC in combination with intravenous cyclophosphamide, intraoral indomethacin, and 
oral zinc.114 Components of the multikine solution included IL-2, IL-1α, IL-1β, GM-CSF, IFNα, TNFα, 
TNFβ, IL-3, IL-4, IL-6, IL-8, IL-10, and macrophage inflammatory protein 1α. Tumors accumulated an 
elevated number of CD4+ T cells and natural killer cells, and the treatment resulted in a 16.7% CR rate. 
Notably, however, this high-powered cocktail led to 8.3% of patients developing sepsis and Wegener 
granulomatosis, suggesting systemic exposure. 
3.2.1 Tumor Retention Mechanisms of Cytokines 
Generally, cytokines in cancer immunotherapy work by stimulating effector cells at the tumor site 
and rely on the host to initiate an immune response against the tumor.106 Ideally, the cytokines should 
localize at the tumor to avoid systemic toxicity, and therefore, it is important to consider the dosage 
concentration, dosage schedule, and route of administration. IT administration typically lacks the severe 
side effects associated with systemic therapies; however, AEs may occur if there is leakage of the IT 
treatment to the systemic circulation.  
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Recombinant human GM-CSF is a 14-35 kDa glycoprotein with 127 amino acids.115 It is composed 
of four bundles of α-helices and is non-spherical with dimensions of 20 Å by 30 Å by 40 Å.116 Since GM-
CSF is a white-blood cell growth factor that promotes the recruitment and activation of dendritic cells and 
monocytes, this cytokine has been studied for use in cancer immunotherapy as an immunostimulatory 
adjuvant to induce anti-tumor immunity.117 Of note, although the GM-CSF have been investigated as an 
immunostimulant for its anti-tumor properties, there is emerging evidence that GM-CSF can potentially 
stimulate tumor growth and metastasis in certain cancers.107 Nevertheless, it is important to limit systemic 
toxicity associated with cytokine therapies. The severe AEs observed in malignant mesothelioma patients 
given intralesional infusion of 2.5-10 mg/kg/day GM-CSF may be a result of systemic exposure.118 
Conversely, lower dosage, daily injections of 15-50 μg or 400 µg GM-CSF given to melanoma patients 
produced milder side effects, likely due to lower systemic exposure.119-120 The lower AEs seen in these 
studies may have resulted from a combination of the lower dosage concentration, or a difference in the 
location and morphology of tumors associated with the cancer type (i.e. mesothelioma vs melanoma). 
Human IL-2 has a molecular weight of 15.5 kDa and is comprised of 133 amino acids.108 IL-2 has 
a hydrodynamic radius of ~3 nm.121 Interestingly, IL-2 can be immuno- stimulatory or suppressive by 
activating cytotoxic effector cells or regulatory T (Treg) cells, respectively.108 These contrasting effects are 
due to differences IL-2 receptor expression patterns; where CD8 + T and natural killer cells express high 
levels of IL-2Rβ (CD122) and IL-2Rγ (γc), while Treg cells express high levels of IL-2Rα (CD25) and only 
intermediate levels of CD122 and γc.108 Typically, high doses of IL-2 is immunostimulatory and generates 
an anti-tumor immune response, while low doses of IL-2 are used for immunosuppression. Similar to the 
effects seen with IT GM-CSF injections, patients with melanoma122-123 responded better to IT IL-2 treatment 
compared to patients with HNSCC124, which may be reflective of differences in tumor morphology between 
melanoma and HNSCC. Moreover, the modification of the IL-2 protein to be conjugated to 6-7 kDa poly-
ethylene glycol (PEG) chains increases the drug’s solubility, improves its half-life, and reduces off-target 
immunogenicity, which translated into better patient responses.125-126 Additional studies have interestingly 
demonstrated that the PEGylation lowered the drug’s affinity for the receptors on Treg cells to a greater 
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extent than the receptors on CD8+ T cells, which resulted in a more favorable CD8+ T cell activation over 
Tregs.127  
One method to limit the systemic exposure of cytokines is to include a tumor-targeting domain onto 
the therapy. For instance, IL-4(38-37)-PE38KDEL is a chimeric protein composed of modified IL-4 and a 
truncated form of Pseudomonas exotoxin (PE), which can target and bind to IL-4 receptor-positive 
glioblastoma cells.128 Likewise, IL13-PE38QQR (IL13PE) is a chimeric protein of IL-13 conjugated to 
truncated PE and binds to IL-13 receptors on malignant glioma cells.129 The IL-2-based immunokine 
(darleukin) and the TNFα-based immunokine (fibromun) further incorporate a diabody derived from the 
L19 antibody to introduce fibronectin binding functionality which capitalizes on overexpression in 
tumors.130 With the absence of the Fc region on the diabody fragment of the antibody, the molecule does 
not interact with FcRn and has a more limited half-life as such. Nonetheless, its smaller size allows for 
better penetration and distribution in the tumor. The combination therapy of darleukin and fibromun (called 
daromun) resulted in AEs that were limited to local injection site reactions.131 This was likely due to the 
antibody-cytokine fusion format of the treatment, which improves the cytokine residence time on the 
injected tumor and allows for the build-up of local cytokine concentration, thereby minimizing systemic 
AEs.  
In summary, cytokines offer the promise of stimulating immunity in the presence of tumors to 
indirectly promote an anticancer response. Cytokines are by nature small and water-soluble, which 
potentially confounds their retention within the TME. Several clinical approaches have sought to address 
these detriments, but the continued development of strategies for the IT administration of cytokines within 
the TME will undoubtedly optimize efficacy while minimizing AEs. These strategies should continue to 
seek modification strategies that do not impede receptor binding or penetration within the tumor.  
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3.3 Viruses and plasmids 
 Oncolytic viruses selectively replicate in tumor cells, causing tumor cell destruction while 
sparing normal healthy cells.132 Oncolytic viruses have been investigated in clinical studies for their ability 
to preferentially infect and kill cancer cells. A variety of virus types have been designed to be oncolytic and 
have been investigated for intratumoral therapy, including adenovirus, enterovirus, herpes simplex virus, 
parvovirus, measles (Rubeola) virus, reoviruses, and vaccinia virus classes.133-143   
Viruses both replicative  (oncolytic) or non-replicative (non-oncoyltic), can be used as vectors to 
carry and deliver foreign DNA into cells with high gene transfer efficiency.144 For instance, talimogene 
laherparepvec (T-VEC/Imlygic®) was approved by the Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) in 2015 for the treatment of melanoma lesions. This modified 
oncolytic herpes simplex virus-1 can selectively replicate in cells and will destroy infected tumor cells.145  
Viruses have been used to express pro-inflammatory cytokines to reap the same benefits as 
exogenous formulations. Several IT viral-based therapies have been designed to express factors such as 
GM-CSF146-147, interferon (IFN)-γ 148-149, tumor necrosis factor-α (TNFα) 150-152, or IL-12.153 Suicide genes 
have also been delivered, such as the bacterial gene called E. coli purine nucleoside phosphorylase (PNP), 
which can convert fludarabine into the anti-cancer agent fluoroadenine.154 Further, the herpes simplex 
kinase thymidine kinase (HSV-TK) has been used to incorporate ganciclovir into a toxic phosphorylated 
compound.155-157 
Although less commonly investigated, another tool for gene delivery includes the use of plasmids. 
Plasmids are sometimes administered alone but are likewise used in tandem with a variety of techniques 
that can enhance gene transfer efficiency such as electroporation or in complex with cationic carriers. For 
instance, a phase 1 clinical study investigated the IT injection of 50 µg of IL-12 plasmid cDNA in patients 
with cutaneous or subcutaneous metastases.158 Plasmids may be delivered with the assistance of 
electroporation to make the cell membrane permeable to the plasmid DNA. For example, electroporation 
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was used to help deliver tavokinogene telseplasmid (tavo), a 6215 bp plasmid that encodes for the p35 and 
p40 subunits of the human IL-12 protein, in metastatic melanoma patients.159-160 
Cationic lipids or cationic polymers are also known to improve gene delivery into tumors by 
inserting through cell membranes.161 Examples of this approach is evident in the use of DC-Chol liposomes 
to form DNA-lipid complexes called lipoplexes162 or the use of polyethylenimine polymers to form DNA-
polymer complexes called polyplexes.71, 163-165 
3.3.1 Tumor Retention Mechanisms of Viruses and Plasmids 
Generally, viruses can be found between 20 and 500 nm in diameter.166 Oncolytic viruses direct the 
killing of tumor cells through cell lysis by infecting tumor cells. Subsequent viral replication, as well as the 
induction of an immunogenic response triggered by the release of tumor cell fragments upon cell lysis 
further compound their effects.132 Oncolytic viruses can be modified to improve their affinity for tumor 
cells while limiting infection in healthy cells by deleting viral genes that will not affect the ability of the 
virus to replicate in cancer cells, but will inhibit viral replication in normal cells.132 For instance, when an 
adenovirus infects a normal cell, the cell expresses the tumor suppressor proteins and the cell undergoes 
cell-cycle arrest or apoptosis, preventing the virus from replicating.  The E1B 55-kDa gene in wild-type 
adenoviruses encodes for a protein that inhibits the tumor suppressor protein p53 and allows viral 
replication to occur. Therefore, adenoviruses that have the E1B 55-kDa gene deleted (such as OsNYX-015) 
would have inhibited viral replication in cells with normal p53 function. However, many tumor cells lack 
functional p53, which allows the E1B 55-kDa gene-deficient viruses to replicate within the tumor and lyse 
the cells. A similar mechanism is used with adenoviruses with the E1A gene deletion (such as DNX-2401). 
E1A binds and inhibits the cellular tumor suppressor protein pRB that is expressed functionally in normal 
cells but is mutated and non-functional tumor cells. Therefore, these E1A gene-deleted viruses can 
selectively replicate and destroy tumor cells, while avoiding replication in normal cells. Similarly, HSV-
1716 is a herpes simplex virus (HSV) type 1 (155 – 240 nm in diameter) with a RL1 gene deletion.139, 167 
This gene encodes for the ICP34.5 protein, which inhibits the double-stranded RNA-activated protein 
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kinase (PKR) protein, a protein that is involved in inhibiting RNA translation and thereby preventing the 
synthesis of viral protein.168 The deletion of the RL1 gene allow for selective replication in tumors with the 
defective anti-viral PKR pathway. The vaccina virus vvDD-CDSR has been mutated to have the viral genes 
encoding vaccinia growth factor (VGF) and thymidine kinase (TK) deleted143. These proteins are essential 
to viral replication, so their deletion prevents the virus from replicating in normal cells. However, viral 
replication in tumor cells is possible due to their upregulation of growth factors and nucleotides.  
Viruses can also be designed to specifically target tumor cells by exploiting alterations in cell 
surface receptors compared to normal healthy cells. For instance, in addition to the E1A gene deletion, 
DNX-2401 also has an RGD-motif engineered into the fiber H-loop.135 This motif enhances tumor 
infectivity/cell entry by allowing the virus to utilize the αvβ3 and αvβ5 integrins enriched on tumor cells. The 
coxsackievirus a21 (CVA21) (~31 nm in diameter) can bind to intracellular adhesion molecule 1 (ICAM-
1) and decay acceleration factor (DAF) proteins that are highly expressed on certain tumor cells.169 The 
live-attenuated measles virus Edmonston-Zagreb vaccine strain (120-250 nm in diameter)170 can bind to 
CD46 that are expressed by some cancer cell lines, making these cells a preferred target.141  
The use of these oncolytic viruses as a monotherapy was generally well-tolerated with mild AEs 
such as injection site pain, fever, fatigue, chills, and flu-like symptoms. However, they have shown varying 
success, where a few treatments led to some clinical responses and others to no clinical responses with 
limited evidence of abscopal effects. A common lack of abscopal effects by oncolytic viruses may suggest 
poor immune activation outside of the primary tumor destruction that occurs as a function of the virus itself.  
 Better clinical responses were observed with the incorporation of transgenes into oncolytic viruses 
for cancer gene therapy. An effective cancer gene therapy requires the delivery therapeutic genes into 
tumors and regulation of gene expression within the tumor microenvironment. A common mode of gene 
transfer is by using a viral vector. As such, the incorporation of transgenes in replicative or non-replicative 
viruses have been designed and used in clinical studies. For instance, FDA approved T-Vec is an attenuated 
herpes simplex virus, type 1 (HSV-1) (155-240 nm) that was engineered to express human GM-CSF. T-
Vec is ICP34.5-deficient (similar to HSV-1716), allowing selective replication in tumor cells.171 Of note, a 
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comparison between intratumoral T-vec and subcutaneous GM-CSF in patients with unresectable stage 
IIIB/C/IV melanoma in a phase 3 trial showed a higher efficacy for T-vec compared to GM-CSF alone.172 
Specifically, the T-vec-treated compared to the GM-CSF alone treated patients had a higher median overall 
survival (OS, 23.3 months vs 18.9 months), durable response rate (DRR) (19.3% vs 1.4%) ORR (31.5% vs 
6.4%), CR (16.9% vs 0.7%), and partial response (PR, 14.6% vs 5.7%), and disease control rate (DCR) 
(76.3% vs 56.7%). Common AEs with T-vec treatment include fatigue, chills, pyrexia, nausea, and flu-like 
illness. However, T-Vec-treated patients had higher instances of grade 3 or 4 AEs compared to GM-CSF-
treated patients (11.3% vs 4.7%), which include fatigue, flu-like illness, injection site pain, vomiting, 
cellulitis, dehydration, deep vein thrombosis, and tumor pain. 
TNFerade uses an interesting technique for the localized delivery of TNFα. TNFerade is a 
replication-deficient adenovirus type 5 that carries a transgene encoding human TNFα. However, a 
radiation-inducble Egr-1 promoter gene was placed upstream to the TNFα cDNA, allowing for control the 
time and location of TNFα delivery through the use of radiation therapy. Ad-RTS-hIL-12 is an adenoviral 
vector that was engineered for the controlled expression of IL-12. This involves the use of the RheoSwitch 
Therapeutic System®, which requires the oral activator veledimex to induce IL-12 expression.153 These 
inducible systems allow the regulation of gene expression, allow for control of when to activate the 
production of the gene product. 
 The popularity of using adenoviruses as a method of gene transfer may be a result of the ability to 
achieve high viral titers, low instances of severe AEs observed in vaccinations with unmodified 
adenoviruses, and higher packaging capacity of genetic information compared with other viruses such as 
the retrovirus.173 However, limitations include the development of immunogenicity against adenoviruses 
that may make repeated treatments ineffective and the limited insert capacity for the length of the coding 
sequence. 
Aside from using viral vectors, genes have been introduced into cells through plasmids, which can 
overcome the limitations associated with viral vectors. For instance, the EGFR antisense DNA is a plasmid 
of pNGVL1-U6-EGFRAS was prepared in phosphate-buffered saline.162 We estimate this plasmid to be 
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about 9600 base pairs; the pNGVL vector (also called pUMVC) is 9287 bp, human U6 promoter is 241 bp, 
and EGFRAS is 39 bp.162, 174-175 The IL-12 plasmid cDNA (pNGVL3-mIL12 ) which was given at 50 µg, 
was also prepared in saline (0.76 mL).158 Since the efficacy of these therapies require their entry into cells, 
the negatively charged nature of plasmid DNA would likely make it difficult for DNA to pass through the 
negatively charged cell membranes.   
One method to facilitate the entry of plasmids into cells would be to use electroporation. The 
application of short electric pulses creates temporary pores or holes in the membrane, increasing cell 
permeability.176 In addition, the applied electric field drives the negatively charged DNA that are on the 
anode end to migrate towards the cell on the cathode end, where the DNA accumulates and interacts with 
the plasma membrane. The DNA enters the cells as endosome-like vesicles. After the application of the 
electric pulses, the cell membrane naturally reseals. For instance, electroporation was used to help deliver 
tavo, a 6215 bp IL-12 plasmid. Clinical responses were fairly similar between treatment the naked IL-12 
plasmid cDNA and tavo with electroporation; however, a direct comparison cannot be made due to their 
difference in plasmid design, study design, and dosage regime. 
Another method to facilitate plasmid DNA entry into cells is by formulating the plasmids with 
cationic polymers to create polyplexes similar to those employed for PAMP immunotherapies. The 
polyplex system masks the negatively charged DNA to feasibly allow the positively-charged polyplexes to 
bind the negatively-charged cell surface of the host mammalian cell and enter through endocytosis.161 For 
example, mixing BC-819 (a plasmid DNA that encodes for the A fragment of diphtheria toxin under the 
control of a H19 gene promoter), with PEI formed polyplexes 80-90 nm in size.177 Also, CYL-02 (a plasmid 
that encodes for the DCK-UMK fusion protein, which phosphorylates and activates the pro-drug 
gemcitabine) was prepared in 5% w/v glucose with a PEI nitrogen to DNA phosphate (N/P) ratio of 8 to 
10. No particle size information was provided for CYL-02; however, we estimate that the polyplexes may 
be around 45 nm based on another reported polyplex with N/P of 8-10 that was made with JetPEI, which 
appears to be the same JetPEI used to make CYL-02.178  
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Together, we surmise that the use of electroporation or cationic polymers will continue to allow for 
better potency compared to the injection of naked plasmid DNA alone. Furthermore, the use of these non-
viral gene therapies eliminates the drawbacks of using viral gene therapies, such as the immunological 
inactivation of adenoviruses and limited insert capacity. However, the non-viral vectors may have non-
specific targets (does not distinguish transfection between tumor and normal cells) and lower transfection 
efficiencies compared to viral vectors. 
3.4 Monoclonal antibodies 
Monoclonal antibodies (mAbs) have shown promising therapeutic efficacy as cancer treatment 
(table 3). Immunostimulatory mAbs can target antigens expressed on the surface of tumor cells and induce 
cytotoxic T lymphocyte (CTL) responses to result in tumor cell death.165 A major class of therapeutic 
antibodies are immune checkpoint inhibitors (ICIs), which target the receptors of inhibitory signaling 
pathways to reverse immune suppression and reactivate immune-mediated antitumor responses.179  
Antibodies targeting CTLA-4 and PD-1/PD-L1 have demonstrated broad activation of tumor-
specific T cells by blocking negative-feedback mechanisms of the immune system. The most common 
administration route of these mAbs is systemic180, however, systemic delivery of mAbs is known to 
potentially induce many immune-related adverse events (irAE), and only 20-30% of patients respond to 
this treatment. IT administration of mAbs has been suggested in attempts to retain mAbs in the tumor 
microenvironment and reduce systemic exposure and associated inflammatory side effects.181 
Ipilimumab (Ipi), a human IgG1 that targets CTLA-4, was the first approved immune checkpoint 
inhibitor for advanced melanoma, and has significantly improved the overall survival rate associated 
with this disease.182 Systemic Ipi administration is commonly associated with a low response rate and 
life threatening toxicities, which has prompted the exploration of IT delivery. A phase 1 ongoing clinical 
trial is testing a combinatorial immunotherapy using IT injection of autologous CD1c (BDCA-1) myeloid 
dendritic cells, ipilimumab, and the PD-L1 blocking mAb, avelumab. Another phase 1 study of IT 
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ipilimumab combined with IL-2 for advanced melanoma found that it was well-tolerated and generated 
responses in both injected and non-injected lesions in a majority of patients.183 T-cells were activated within 
the tumor and in the draining lymph nodes, indicating IT administration enhanced the local anti-tumoral 
responses and also induced distal effects.  
CD40 is a member of the TNF receptor family expressed on the surfaces of APCs and B cells. The 
CD40 ligand, CD154, is mainly expressed by activated T cells and B cells. CD40 ligands assist T cell 
activation and differentiation, which results in increased tumor-specific antigen presentation and the 
production of CTLs. Despite its potential synergy with other forms of anticancer therapy, the use of CD40 
agonists has been associated with toxicities including cytokine release syndrome, thromboembolic events, 
and tumor angiogenesis. Collectively, these detriments substantiate CD40 ligands as candidates for IT 
immunotherapy to refine their delivery profiles. ADC-1013 is a human IgG1 agonistic CD40 antibody that 
has been investigated in human via both IT and IV administration in advanced solid malignancies. Although 
the main delivery method of ADC-1013 has been IV, a phase I trial for IT administered ADC-1013 in 
patients with advanced solid tumors has shown safety and B cell expansion after treatment, which could be 
related to the antitumor efficacy.184-185  
3.4.1 Tumor Retention Mechanisms of Monoclonal Antibodies 
The administration of immune checkpoint inhibitors including CTLA-4, PD-1 and PD-L1 
downregulates the suppression of T cells and improves their activation. Binding of co-stimulatory receptors 
such as CD40 and OX40 is important for turning non-immunogenic (“cold”) tumors “hot”. These co-
stimulatory receptors are mainly expressed on APCs, and when activated, the presentation of tumor antigens 
is increased and cytokines are released to improve the activation of anti-tumor T cells. Immunostimulatory 
mAbs are commonly administered as IV infusions, but so far only a small fraction of cancer types are 
successfully treated by mAbs. Severe irAEs have been prevalent with these therapies. irAEs are mostly 
attributed to be induced by the inhibition of immune checkpoints that are naturally in-place to prevent 
autoimmunity. Therefore, when checkpoints are inhibited outside of the TME, autoimmune responses can 
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ensue. The small size of mAbs (~10 nm) is a likely contributor to rapid clearance and dispersion out of an 
injection site and into systemic circulation.186  
Local administration of immunotherapeutic mAbs can restrain immune responses to the tumor site 
and minimize unwanted systemic activation of the immune system by reducing leakage from the tumor. So 
far there are a limited number of slow-release systems for injected antibodies that largely use emulsions or 
micro/nano-formulations. Anti-CD40 has been conjugated to immunostimulatory poly(γ-glutamic acid) 
nanoparticles to successfully improve localization of the mAb as the nanoparticle minimized systemic 
cytokine release.187 However, the coupling of anti-CD40 to polylactide nanoparticles did not show an 
improvement of anti-tumor activity.188 Other anti-CD40 formulations based on mineral oil or dextran-based 
microparticles have shown the capacity to activate tumor-specific T cell responses and significantly 
decrease the AEs compared to systemic infusion, but the microparticles caused overly severe local 
inflammation.189  
AEs including local inflammation and pain at the injection site are most commonly observed for 
the IT clinical trials investigating mAbs. One of the critical concerns of IT administration is the dispersion 
of the antibody following injection. Local administration of antibodies has shown increased accumulation 
in the tumor-draining lymph nodes, which may assist in generating anticancer immunity.190 ADC-1013 has 
been optimized through the use of Fragment Induced Diversity (FIND) technology to improve binding 
affinity.191 This optimization makes it possible to achieve high efficacy with very low doses. To further 
facilitate TME retention, mAbs can be engineered to accumulate in the tumor site. Antibodies with a high 
isoelectric point can be better retained in the TME as it is more acidic than normal tissues. Also, antibodies 
with increased binding affinities at lower pH are known to increase the activation of antitumor responses.192   
Together, IT antibody delivery offers the potential for increased potency with mitigated risk. As 
antibodies are produced as highly specific, high-affinity proteins, colocalization with the TME where 
cognate receptors abound should facilitate IT retention. Alternate approaches formulating these biologics 
with particles and emulsions may also favor retention, however more work should be done to strike a 
tolerable balance between anti-tumor immunostimulation and uncontrollable local inflammation. 
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3.5 Small Molecules  
Small molecule drugs have provided the most storied historical benefit for immuno-oncology 
therapies over many decades. Compared to large molecules that often have long half-life and poor tissue 
penetration, small molecules have the advantage of an <24hr half-life and can more readily cross cellular 
membranes. Together, these properties aid with intermittent dosing that can reduce toxicity and side effects. 
Small-molecule oncology drugs invoke various mechanisms like checkpoint inhibition, 
immunomodulation, and cytotoxic chemotherapy.  
One of the most extensively studied and widely utilized chemotherapy drug is cisplatin. Cisplatin 
[cis-diammineplatinum dichloride] has been used to treat lung, bladder, and head and neck cancers. 
Significant systemic toxicity has been a limiting factor for further use, and thus IT formulations have been 
investigated. Currently there are several cisplatin-based IT delivery systems in clinical trials. INT230-6 is 
a supermolecular complex of cisplatin, vinblastine, and an amphiphilic penetration enhancer that assists 
dispersion in tumors and diffusion into tumor cells. Intratumoral injections of INT230-6 for solid tumors 
resulted in an 80% CR rate.193  
3.5.1 Tumor Retention Mechanisms of Small Molecules 
Small molecule drugs are versatile for therapeutic design because of the ease of modification, 
intervention and formulation, and the flexibility for better management of AEs that is conferred by a 
relatively short half-life. In contrast to large-molecule therapies like mAbs, which primarily target 
extracellular ligands and receptors, small molecules have enhanced vascular permeability that can target 
intracellular components with potentially faster penetration and homogenous distribution into solid tumors 
that can achieve greater response rates. Chemotherapeutics were designed to rapidly interrupt cancer cell 
proliferation through multiple mechanisms. Alkylating agents like cisplatin bind DNA through covalent 
bonds and prevent DNA replication. Anti-metabolites like gemcitabine resemble nucleobases by their 
structure, and once incorporated into DNA, inhibit the enzymes involved in DNA synthesis.194 
31
One of the most critical challenges in the development of small molecule antitumoral drugs is the 
rapid plasma and tumor clearance due to their small size and molecular weight. Therefore, therapeutic 
molecules have been widely applied as IV infusion in free, unmodified forms. However, as IT injection 
these compounds are commonly modified into a prodrug or formulated with large molecules and carriers 
to improve retention. Several delivery systems are under clinical trials including polymer-drug conjugates, 
liposomal carriers, and polymeric micelles.195 The performance of these formulations can be affected by 
multiple physicochemical characteristics including particle size, composition, stability, and surface 
properties. The particle size and surface charge have shown large influence on the cellular uptake and tumor 
distribution. It has been observed that particles with size <200nm are able to penetrate and distribute into 
tumors after IT injections.196 Many polymeric formulations of cisplatin are sized 60 to 450 nm.197-199 The 
composition of the delivery system includes non-toxic, non-immunogenic, biodegradable, and 
biocompatible polymers like PEG and PLGA, to support a controlled-release system while minimizing the 
dispersion into systemic circulation. The formulation developed by Chen et al. has shown an extended 
release and higher maximum-tolerated dose (MTD) than the free cisplatin, as well as significantly tumor 
suppression effect for HNSCC.200 In the trials of Celecoxib, hydrophobic vitamin D was used as a carrier 
to potentially solve the low solubility issue of the drug and increase the depot effect at the tumor site. 
However, extensive hydrophobicity might increase non-specific serum protein binding, which can be 
avoided by PEGylation to provide a hydrophilic surface that can prevent access of proteins.  
Small molecule drugs enter tumors mainly through non-selective diffusion and passive targeting, 
so an ideal form of these molecules is likely nonionized to fully enable conductive diffusion. The acidic 
microenvironment of tumor tissue causes chemoresistance against weak-base drugs, which become 
protonated and positively charged upon entering the tumor and are less membrane permeable. Alkylation 
drugs including Cisplatin (pH 3.5-5.5) and Gemcitabine (pH 2.7-3.3) remain nonionized and have higher 
cytotoxicities at lower pH. The effect of surface charge on nanoparticles has been investigated on many 
nano-sized formulations as well. It was observed that positively charged particles retain in the tumor at 
higher concentrations compared to the surrounding tissue201 and diffuse out at a slower rate in comparison 
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to anionic particles.202 Together this observation is attributed to the electrostatic interactions with negatively 
charged proteoglycans of the tumor neovasculature. For highly charged particles like gemcitabine 
hydrochloride and PV-10, a disodium salt, the electrostatic interactions might be a significant limitation to 
their mobility within the tumor, which could affect the efficacy of IT injections. 
As small molecules are largely unhindered by the transport phenomena that dictate the distribution 
of other classes we have discussed in this review, chemical modifications can serve to selectively impede 
egress from the TME. Non-specific binding of small molecules to tumor cells or the extracellular matrix 
components can enhance the retention within the tumor. Ligand-receptor binding also delays clearance. 
Polymerization and complexation of small molecules enables their retention and depot-release within the 
TME. Tuning the charge properties of small molecules has also shown to aid intracellular penetration of 
these compounds as well as retention in the tumor. IT delivery of small molecules is appealing because the 
lower specificity of these candidates’ mechanism can be overcome by the physical retention of their 
presence at the TME. However, in cancers where multiple tumor sites are present, it may not always be 
feasible to elect this strategy as an abscopal effect is unlikely when the immune system is not invoked. 
4. Conclusion 
This review set out to emphasize the impact of therapy biophysical characteristics on safety and 
efficacy by associating IT cancer therapies currently in clinical trials with their respective characteristics 
or formulations. While depending on the mechanism of action and target, it may be said that therapies 
with modifications to the active or those formulated to be more than aqueous demonstrated increased 
safety profiles. For intratumoral delivery, one theory could be that formulation or design of therapy that is 
larger, or particulate in nature may be connected to increased safety due to increased injection site 
retention. Overall, this review was intended to help future researchers realize the importance of design 
when considering an IT cancer therapy. Current cancer therapy strategies are vast in type and mechanism 
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therefore the target and function have to be the primary consideration in the design, however, the 
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Immunotherapy is a powerful form of cancer treatment that harnesses the body’s own immune 
system to fight cancer. Therapies range from checkpoint inhibitors to decrease immune suppression, 
adoptive T cell transfer using autologous cells engineered to express chimeric antigen receptors against 
tumor antigen, monoclonal antibodies that can mark tumor cells for killing, and immunostimulants like toll-
like receptor agonists, cytokines, or bacteria.1 Immunostimulants, or compounds that activate innate 
immune responses, are particularly useful for surmounting the suppressive tumor microenvironment. The 
tumor microenvironment employs a variety of immune evasion and suppression techniques, including 
suppressive cell subtypes, cytokines, T-cell exhaustion, and even downregulation of tumor antigen 
expression.2-5 The use of immunostimulants in the presence of tumor antigens causes a number of reactions 
including upregulation of co-stimulatory molecules, increased antigen presentation, and secretion of 
proinflammatory cytokines which can induce tumor specific T-cells.6-8 Immunostimulants, however, can 
induce off-target side effects by causing improper activation of the immune system in healthy tissue, thus 
beckoning improved delivery systems. 
Toll-like-receptor agonists are a class of immunostimulants capable of inducing strong T cell 
activation after binding to their respective toll-like receptors (TLRs). TLRs recognize bacterial and viral 
pathogen associated molecular patterns (PAMPs), which then trigger pro-inflammatory, innate immune 
responses. Only two TLR agonists are currently FDA approved. The TLR4 agonist monophosphoryl lipid 
A (MPL) is incorporated into the adjuvant system for Ceravarix™, a cervical cancer vaccine.9 In Aldara™, 
a cream for superficial basal cell carcinoma, the main active ingredient is a TLR7/8 agonist called 
imiquimod.10 Currently there are many immunotherapy clinical trials utilizing TLR agonists either alone or 
in combination with other immunotherapy strategies like checkpoint inhibitors.11 
Many research efforts and clinical trials have explored the use of polyI:C 
(polyinosinic:polycyticylic acid) and CpG, two TLR agonists with the ability to induce strong pro-
inflammatory responses after binding to their respective TLRs. PolyI:C is a TLR3 agonist consisting of 
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double-stranded (ds) RNA that resembles viral RNA and has shown both antiviral and anticancer activity.12-
13 Furthermore, TLR3 agonists have demonstrated the ability to directly inhibit tumors in vitro by 
decreasing proliferation and inducing apoptotic cell death.12 CpG is a short, single-stranded unmethylated 
synthetic oligonucleotide resembling bacterial DNA that agonizes TLR9.14 Both TLR3 and TLR9 are 
located within endosomes, therefore the immunostimulants must be endocytosed to reach their target. While 
both polyI:C and CpG are promising candidates for use in cancer immunotherapy, one major challenge is 
determining how to properly deliver these potential therapies to tumor tissue.  
Traditional systemic delivery offers the potential to target multiple tumor sites, however, full body 
exposure of immunostimulants can cause improper activation of the immune system in healthy tissue, 
causing inflammation and generating autoimmune reactions.15 Intratumoral (IT) delivery offers a possible 
solution with an aim of generating anti-tumor immune responses capable of reaching distal tumor sites 
concurrently with shrinkage of treated tumors. This process, called the abscopal effect, can occur when 
tumor-activated immune cells drain to lymph nodes and circulate to distal cancer loci.16 In this work, we 
aim to create a formulation of polyI:C or CpG that will be retained at the site of injection to avoid systemic 
toxicity and facilitate intracellular delivery.  
Poly-L-lysine (PLL) is a highly positively charged polycation that has been extensively utilized as 
a delivery tool in intracellular genetic material (DNA or RNA) delivery research.17-20 In fact, a candidate 
drug called Hiltonol, consisting of polyI:C combined with PLL stabilized by carboxymethylcellulose, has 
been seen some success as a vaccine adjuvant and as an immunostimulant in cancer therapy.21 Where DNA 
alone would be small and have electrostatic repulsion from cell membranes, formulation of DNA into 
polycationic complexes compacts DNA into a particle and allows for attraction to cell membranes followed 
by endocytosis and lysosomal release once inside the acidic conditions of lysosomes. While similar 
polyplexes have been broadly explored in their capacity to deliver genetic material intracellularly, less work 
has been conducted on the formulation and transport of polyplexes and intracellular delivery of TLR 
agonists.  The current study was focused on exploring the relationship between PLL molecular weight and 
complexation, TLR activation, and transport in a simple, simulated tumor microenvironment. Various 
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characterization methods were employed including particle sizing, and zeta potential but also experiments 
to assess the accessibility of the TLR agonist within the polyplex. To evaluate injection site retention, 
polyplexes were tested in an assay to emulate transport in human tissue. Finally, HEK blue TLR cells were 
used to assess the ability of the complexed TLR agonist to activate its respective TLR in vitro. Overall, this 
work illuminates the possibility of an additional purpose for polycationic polyplexes in cancer 
immunotherapy and emphasizes the importance of optimizing physiochemical properties of IT delivery 
systems. 
2. Methods 
2.1 Polyplex formation 
Poly-L-lysine (K9) was purchased from Biomatik (Cambridge, Ontario, Canada). Poly-L-lysine 
hydrobromide of lengths K20 through K250 were purchased from Alamanda Polymers (Huntsville, AL). 
Poly-L-lysines will be referred to generally as PLL or specifically as poly(number of lysines).  CpG ODN 
1826 and LMW polyI:C were purchased from Invivogen (San Diego, CA). The average molecular weight 
(MW) of the individual polyplex components is provided in table 1. PLL polyplexes with CpG ODN 1826 
or LMW polyI:C were prepared in 4% mannitol by adding equal volumes of pre-diluted PLL and pre-
diluted CpG or polyI:C followed by repeated pipetting for 30 seconds (figure 1). The polyplexes were then 
stored at room temperature for a minimum of 20 minutes before measurements or cell culture use. 
Polyplexes were prepared at varying mass ratios of 0.5, 1, 2, 3, 5, 10 that represent mass of PLL divided by 
the polyplex partner, CpG or polyI:C. Mass ratio was utilized rather than a N:P ratio due to heterogeneity 
of the components. Supplementary table 1 contains a translation of mass ratio to molar ratio which for 
PLL+CpG polyplexes is exact and for PLL+polyI:C polyplexes is based on the median average MW of 
polyI:C. For PLL+CpG polyplexes N/P ratio can be calculated and is available in supplementary table 2.  
68
2.2 Agarose gel electrophoresis 
Agarose was purchased from Sigma Aldrich (St. Louis, MO). Tris-acetate-EDTA (TAE) buffer was 
purchased from Invitrogen (Carlsbad, CA). PLL + CpG or polyI:C polyplexes were prepared as described 
holding the CpG or polyI:C concentration constant while varying the PLL concentration. Then, 4 µL 6x 
DNA Loading dye (Takara Bio Inc., Japan) was added to 10 µL of the polyplex and subsequently 12 µL 
was loaded onto a 3% agarose gel, and electrophoresed for 25 minutes at 100 V. CpG and polyI:C alone 
were run as controls and a 1 kb bench top DNA ladder (Promega, Madison, WI) was used. The gel was 
stained using SYBR Gold (Invitrogen, Carlsbad, CA) in TAE buffer for 25 minutes, shaking at room 
temperature then imaged on AlphaImager (Protein Simple, San Jose, CA). 
2.3 Particle sizing 
The effective radius (nm) of PLL + CpG or polyI:C polyplexes was determined by dynamic light scattering 
(DynaPro, Wyatt Technology, Santa Barbara, CA). Samples for particle sizing were prepared in 4% 
mannitol (Sigma Aldrich, St. Louis, MO). Measurements were conducted after a minimum of 20 minutes 
of incubation at room temperature.  
2.4 Zeta potential 
Zeta potential measurements were measured by Zeta PALS (Brookhaven Instruments, Holtsville, NY). All 
samples for zeta potential measurements were prepared in 4% mannitol and diluted into 1 mM KCl for 
analysis.  
2.5 Scanning electron microscopy (SEM) 
SEM images were captured using Hitachi SU8230 field emission scanning electron microscope at the 
University of Kansas Microscopy and Analytical Imaging Laboratory. Polyplexes or individual components 
were added to carbon coated grids and touched on a Kimwipe to remove excess liquid, then immediately 
dipped into liquid nitrogen prior to imaging.  
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2.6 Assessment of DNA/RNA accessibility by SYBR gold staining 
The degree of accessibility of the DNA or RNA following complexation with PLL was assessed by the 
staining of SYBR Gold to accessible DNA or RNA. Polyplexes were made as described above and after 20 
minutes polyplexes were added to a 96-well plate in triplicate followed by SYBR gold stain and mixed 
well. After approximately 5 minutes the fluorescence was measured using a Synergy H4 microplate reader 
(BioTek, Winooski, VT). The excitation filter was set to 495 nm and emission filter to 537 nm. 
2.7 Hyaluronic acid gel retention 
To test the polyplexes ability to retain at an injection site, we devised a model in vitro system to evaluate 
transport in human tissue made of highly viscous hyaluronic acid (HA) to which we could inject labeled 
polyplexes in the center and watch it spread over time. 0.8-1.5 MDa HA was added to PBS buffer at 20 
mg/mL then placed on end-over-end rotator overnight to dissolve. The HA gel was then weighed out into 
a 96 well black plate at 0.28 g/well. The plate was centrifuged to remove bubbles then placed at 4 ˚C until 
use. Polyplexes were prepared as described but for this test they were first made up in 90% of the total 
volume, let incubate for 20 minutes, then 10% of the total volume of 20x SYBR Gold stain was added for 
an additional 5 minutes. A 3D printed device was designed to allow uniform injection into the wells at half 
the depth of the gel. 7 µL of sample was injected through the device into the center of the well using reverse 
pipetting. Fluorescent images were obtained at varying time points on a MaestroFlex Imager (Cambridge 
Research and Instrumentation, Woburn, MA). A control placed in each image was used to normalize the 
intensity across all images. To further normalize the data, a percent reduction was calculated based on the 
intensity at time 0 between pixels 15-25 as depicted in figure 8A.  
2.8 In Vitro HEK blue reporter cell assay  
HEK-Blue TLR9, TLR3, and Null cell lines (Invivogen, California) were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Corning, NY) supplemented with 10% FBS, 1% penicillin-streptomycin, and 
the selective antibiotics according to the manufacturer’s protocol. HEK-Blue TLR cells allow for the study 
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of TLR activation by observing the stimulation of SEAP, a protein associated with downstream activation 
of TLRs. At 50-80% confluency, cells were harvested and resuspended in HEK detection media (Invivogen, 
California) and 180 uL was seeded into 96-well plates at ~8x10^5 cells/well. 20 uL of treatment were added 
to respective wells and the plate was incubated at 37 °C, 5% CO2 for at least 6 hours or until color change. 
Absorbance readings were measured at 640 nm. Null cells were used as a control. Concentration of polyplex 
for the study was determined based on a titration of polyI:C or CpG (Figure# slide15). PolyI:C was held 
constant at 200 µg/mL and CpG was at 100 µg/mL.  
3. Results 
3.1 Polyplex formation 
Agarose gel electrophoresis studies were used to visually test the ability of the different molecular 
weights of PLL to complex with the polyanionic TLR agonists. Free polyI:C or CpG migrated freely 
through the agarose gel whereas PLL did not. When polyI:C or CpG are complexed with PLL, the material 
retained in the loading well. The agarose gels in figures 2 and 3 show the differences in the interactions 
between PLL and polyI:C or CpG. PLL mass was increased, increasing the mass ratio, while the polyanion 
counterpart was held constant. The immobilization of polyanion was seen in every PLL polyplex and 
occurred at a lower ratio for the higher MW PLL’s. For all studied polyplexes, full immobilization was seen 
by a mass ratio of 1.5.  
3.2 Polyplex characterization 
Zeta potential measurements (figure 4) agreed with the agarose gels. A net positive charge emerged 
at the same mass ratio where the TLR polyanion agonist was immobilized on the gels. At higher ratios, the 
zeta potential started to plateau, indicating PLL had saturated the surface of the polyplexes.  
Particle size is also an important consideration, since size has been shown to impact cell uptake, trafficking, 
and ultimately immune activation.22-27 For all CpG-containing polyplexes the radius was between 20 and 
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100 nm (figure 4). Polyplexes with polyI:C were unable to be measured by DLS or zeta potential due to 
heterogeneity. To corroborate particle sizing data, SEM images were collected and the results correlate with 
the particle sizes determined by DLS measurements (figure 5). Control solutions of PLL or TLR agonist 
lacked visible particles. In the CpG polyplex samples, many dark spherical particles were seen within the 
expected size range. PolyI:C polyplexes did not result in spherical particles, which validates the 
unsuccessful DLS measurements.  
3.3 SYBR gold accessibility 
To investigate how PLL encapsulates or polyplexes with the polyanions, we utilized a DNA/RNA 
stain to measure accessibility of the polyanion. In this experiment the polyanion concentration is held 
constant. Free polyanion was more accessible whereas complexed polyanion was more encapsulated and 
inaccessible. To compare between different MW PLL’s, figure 6 graphs show the fluorescence intensity 
normalized to the intensity of the respective control, either polyI:C or CpG. Any value under 1 implies 
some amount of immunostimulant encapsulation by the PLL. In general, the fluorescence decreased as the 
ratio increased suggesting increased encapsulation. Gel electrophoresis data previously indicated that the 
immunostimulant was fully immobilized by a ratio of 1.5, yet the K9 polyplexes appeared to have some 
accessible immunostimulant at all ratios than the higher MW PLLs. The strength of the interaction appeared 
weaker for lower molecular weights of PLL and at lower ratios of PLL to the polyanions.  
3.4 Hyaluronic acid gel retention 
To simulate tumor retention of polyplexes in correlation with the ratio of polycation to polyanion, 
we injected sample into a viscous HA gel and diffusion of the TLR agonist polyanions was monitored over 
time. HA is a major component within the tumor and high molecular weight HA has been used to model 
subcutaneous (SC) space injection simulators.28-29 For typical SC injection site simulations, 10 mg/mL HA 
has been used. To model a denser tumor environment, the HA concentration was increased to 20 mg/mL. 
The negative charge of HA emulates extracellular matrix and we hypothesized positively-charged 
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polyplexes would remain at the injection site in the center of the well longer than polyI:C or CpG alone. 
The controls, polyI:C and CpG alone diffused quickly, even within two hours (figures 7&9). For both sets 
of data, the lower MW PLL polyplexes diffused much more than higher MW PLLs. Furthermore, in some 
of the higher MW PLL sample wells, a “donut” shaped spot was formed likely due to immediate aggregation 
following leaving the pipette (figure 7). Due to MW differences, the ratios cannot be directly compared 
between polyI:C and CpG polyplexes however we can say that at the same mass ratios, the CpG polyplexes 
have a greater potential of retention than the polyI:C polyplexes with the same PLL. Since the polyplexes 
were labeled using SYBR Gold stain, each polyplex stained slightly differently depending on the 
accessibility of the polyI:C or CpG. To make the retention comparable between samples, a percent reduction 
was calculated. Figure 8B&C show percent reductions at 2 and 5 hours, where the greatest differences 
were observed. Figures 10 and 11 have the percent reduction for every time point next to the respective 
spatial plots. For both polyI:C and CpG polyplexes, the percent reduction was increasingly influenced by 
ratio as the MW of PLL was increased. In all but the K9 polyplexes where ratio seemed to be independent, 
the percent reduction decreased with increase in ratio. CpG polyplexes had less dispersion from the center 
than polyI:C polyplexes at all PLL sizes above K9.  
3.5 In vitro HEK blue reporter cell assay 
PolyI:C and CpG are TLR agonists of TLR3 and TLR9, respectively. In our approach, their activation 
is crucial in the stimulation of the desired immune response. To examine the effect of complexation on TLR 
activation, we utilized HEK blue hTLR reporter cells. The polyplexes and controls were tested in the null 
cell line and reporter cell lines for their respective TLRs. Samples were run in the null cell line as an 
additional control. Polyanion concentrations were determined by selecting a concentration that achieved a 
reasonable response factor as shown from a concentration curve completed in the respective cell lines 
(supplementary figure 1).  Polyplexes were made as previously described by holding the polyanion 
concentration constant and increasing the mass ratio of PLL. TLR activation in HEK blue cells could be 
detected by absorbance using the HEK blue detection media. Figure 12-13 graphs show the absorbance of 
73
the samples minus signal produced by PLL control normalized to the polyanion control. Figure 14 
combines the activation data to relate PLL length and ratio. Therefore any value above 1, reflects that the 
sample activated the TLR better than the polyanion alone. K20 and K30 polyplexes were only tested with 
CpG since polyI:C polyplexes were not yielding promising results. None of the polyI:C polyplexes were 
able to activate TLR3 as well as the polyI:C alone. On the other hand, some of the lower ratio CpG 
polyplexes activated TLR9 as well as the CpG control. In both data sets, K9 polyplexes provided better 
TLR activation than higher MW PLLs. CpG polyplexes appeared to have a greater dependency on ratio 
than polyI:C polyplexes where an increase in ratio led to decrease in activation- an expected result 
considering the decreased accessibility of the immunostimulant. For CpG polyplexes, the activation showed 
a dependency on PLL length except at R0.5, or at a lower concentration of PLL. Interestingly, there 
appeared to be a range of PLL length at which the activation of TLR is more dependent on the ratio. For 
polyI:C this is around K50 and for CpG, any tested PLL length over K9. In addition to the TLR activation, 
cellular metabolism was also measured in the respective HEK cells using a resazurin assay. It is well known 
that higher MW PLL’s can cause toxicity in cells therefore we aspired to find a range in which there was 
limited cellular damage and acceptable TLR activation.30  Figure 12-13 shows metabolism of cells 
incubated with polyplexes adjacent to the corresponding PLL to show that the metabolism is directly a 
result of the PLL’s effect on the cells.  Figure 15 combines the metabolism data to compare the PLL length 
and the ratio. Bear in mind the concentration of PLL in the CpG polyplexes is half of the concentration in 
the equivalent polyI:C polyplexes. The metabolism was highly dependent on both PLL length and 
concentration (ratio). At K9, the metabolism was not affected by ratio/concentration but with increase in 
PLL length, the metabolism decreased with ratio increase. The CpG polyplex’s metabolism profile showed 
a dependence on concentration more so than PLL length (ratio=concentration and clear pattern) whereas 
the polyI:C polyplexes were only dependent on concentration up to K50. At ratios above R0.5, polyI:C 
polyplexes yielded metabolism dependent on PLL length- with values being close together regardless of 
ratio. The metabolism data matched the TLR activation trends especially in the CpG polyplexes’ 
dependency on ratio.  
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4. Discussion 
The use of the immunostimulants, polyI:C and CpG, to overcome the suppressive tumor 
microenvironment has shown great promise. The IT route of delivery circumvents trafficking and 
penetration into the tumor, but transport of therapy out of the tumor tissue and into systemic circulation is 
still an issue. IT clinical trials have demonstrated the necessity to optimize the retention of potent 
immunostimulants to decrease systemic toxicity.31-32 Many approaches have suggested enhanced efficacy 
and safety when the TLR agonist is structurally modified or formulated into an emulsion or complex.21, 33-
37 Polycationic delivery vehicles have frequently been utilized for intracellular delivery of negatively 
charged genetic material by packing it into a net positively charged complex.38-39 Here, we evaluated 
polyplexes of the polycation PLL with polyanionic TLR against. Specifically, we examined the relationship 
between PLL molecular weight and complex formation, TLR activation, and retention in a simulated tumor 
microenvironment.  
All molecular weights of PLL tested were found to fully complex with both polyI:C and CpG as 
indicated by agarose gel electrophoresis. Interestingly, it appeared that the PLL MW did not have a 
significant impact on the ratio at which the immunostimulant became fully complexed but this could be 
elucidated by testing a smaller range of lower ratios. While immobilization is important, the biophysical 
characteristics of the particles like size and charge play a major role in determining transport and cell uptake 
following injection. While results vary depending on route of administration, a general understanding for 
transport after injection is that for uncharged particles <4 nm drain to systemic, particles between 10-100 
nm drain to lymphatics, and particles >100 nm tend to form depot or retain at the injection site or are 
trafficked after being taken up by antigen-presenting cells (APCs).40-42 One study evaluated therapy 
clearance from tumor space after intratumoral injection of small or large emulsions, and neutral or cationic 
liposomes.22 They found that larger (120-250 nm) particles and cationic particles have increased tumor 
retention in comparison to smaller or neutral particles. Interestingly, they also concluded that the rate of 
transfer from the poorly-perfused area to well-perfused area is the determining factor for IT transport and 
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not the rate of transfer from interstitial space to the vascular side. Further, the efficacy of TLR agonists, 
polyI:C and CpG, require intracellular delivery to reach endosomes, which is typically optimal for 
positively charged particles 20-500 nm in diameter where the mechanism of uptake can differ based on the 
size.30, 40-41, 43-45  
DLS and SEM measurements showed that PLL+CpG polyplexes formed spherical particles 
between 50-200 nm in diameter. For CpG polyplexes, the K9 group had a slightly greater diameter than the 
higher MW PLLs which could be a result of a different complex arrangement, or a weaker electrostatic 
interaction of the polyplex at lower MW PLL’s. On the other hand, the PLL+polyI:C polyplexes did not 
form particles measurable by DLS or EM methods. The discrepancy between the two immunostimulants 
may be explained by structural differences between dsRNA (polyI:C) and ssDNA (CpG). Previous research 
has indicated that dsRNA resists condensation, or complexation in comparison to ds or ssDNA due to spatial 
and distribution of electrostatic potential differences.46-47 For Lynn et. al., the formation of a particle by 
their TLR-7/8 agonist candidate was found to be critical for duration of innate cytokine production and 
reduced systemic toxicity.48 Specifically, they found that while increased therapy retention was necessary, 
it was not sufficient for enhancing the immune response; only particles were properly taken up by APCs 
leading to increase in innate activation.  
Model injection site retention experiments confirmed that PLL polyplexes remain at the injection 
site longer than immunostimulant alone.  While agarose gel electrophoresis for both polyI:C and CpG 
polyplexes indicated immobilization at similar ratios, the diffusion profiles in concentrated HA were 
different, suggesting retention may have some dependency on the formation of spherical particles only seen 
with CpG polyplexes. We saw increased retention by the polyplexes that formed particles which agrees 
with the previously described research that showed particle formation does increase in vivo retention and 
persistence in lymph nodes in comparison to non-particulate material.48 For both polyplexes, K9 was 
insufficient for retention even at higher ratios where there appeared to be complete immobilization. Since 
the fluorescence label was on the immunostimulant, the differences in retention could be explained by a 
weaker interaction strength between polyI:C and PLL compared to CpG polyplexes as well as K9 
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polyplexes versus higher MW PLL. Higher MW PLL and larger ratios increase retention overall, however 
CpG polyplexes appear to have superior retention abilities. 
In addition to biophysical transport considerations, efficient activation of the TLRs after 
complexation with polycation is significant for determination of therapeutic efficacy. Only a few of the 
lower ratio and lower MW CpG polyplexes were able to activate the target TLR as well as CpG alone. For 
all polyplexes, the lowest ratio had the highest TLR activation, and at higher ratios, the increase in MW 
PLL led to decreased activation. Taken together with resazurin data, it is likely that the decrease in 
activation at higher ratios and MWs of PLL was due to toxicity caused by the PLL except in the case of K9 
whose efficacy was not dependent on ratio (concentration). Some evidence suggests that a PLL MW larger 
than 3000 Da is required to complex with DNA effectively.20, 49 Higher MW polycations have enhanced 
intracellular delivery potential, however, there is also an increase in cellular toxicity.38, 50-51 Futhermore, 
while larger ratios may be more efficient at intracellular delivery, the lower ratio polyplexes are more potent 
at activating TLR which could be attributed to decrease in immunostimulant availability at higher ratios.30, 
38 Availability of the immunostimulant evaluated by SYBR Gold staining indeed showed that lower ratios 
have more available immunostimulant and that polyI:C seems to be less accessible in a comparable polyplex 
of CpG. More accessible immunostimulant with K9 polyplexes could potentially be explained by a weaker 
polyplex interaction strength which may also account for the lack of dependency on ratio in the TLR 
activation experiments. Thus, there must be a balance between the ratio of PLL to immunostimulant and 
the MW of PLL such that there is and sufficient complexation for intracellular delivery, but a weak enough 
interaction to allow immunostimulant to reach its target once endocytosed, increased retention and minimal 
cell toxicity. The lowest MW PLL, K9 was insufficient for increasing retention and the highest MW PLLs 
induced cytotoxicity. Our results indicate that the ideal PLL length appeared to lie above K9, up to K50.  
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5. Conclusion 
 Immunostimulants for immunotherapeutic treatment of tumors are powerful weapons, however, 
delivery methods need to be optimized for minimizing systemic toxicity and maximizing retention at the 
injection site. For negatively charged immunostimulants like many TLR agonists, formulation with a 
polycation has resulted in increased intracellular delivery. Here, we present results that demonstrate the 
potential for polycations in polyplexes to aid in injection site retention for minimized systemic exposure of 
immunostimulants. TLR activation was largely driven by the MW of PLL followed by the accessibility of 
the immunostimulant within the polyplex. Retention was also driven by these factors but in an opposite 
manner. Taken together, we believe that there is an optimal window of polycation MW and ratio that favors 
TLR activation and retention without causing toxicity. For CpG polyplexes, K9 through K50 was ideal for 
limiting cytotoxicity but higher MW was best for retention. Furthermore, this work supports with the 
hypothesis that particle formation is critical for immune activation and retention. These findings illustrate 
the potential use of polycations for carrier vehicles that not only aid in intracellular delivery but also 
contribute to injection site retention. The characterization results in this work suggest that PLL+CpG 
polyplexes may be a good candidate for increased intracellular delivery and decreased transport away from 
the tumor. Future studies could optimize the molecular weight and composition of the polycation such that 
the polyplex interaction strength allows for efficient TLR activation, the biophysical characteristics 





















Figure 2. Agarose gels of PLL+CpG polyplexes. (A) K9+CpG, (B) K20+CpG, (C) K30+CpG, (D) 




Figure 3. Agarose gels of PLL+polyI:C polyplexes. (A) K9+polyI:C, (B) K20+polyI:C, (C) 
K30+polyI:C, (D) K50+polyI:C, (E) K100+polyI:C 
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Figure 6. Effect of PLL molecular weight and mass ratio on accessibility of polyI:C or CpG using SYBR 
Gold assay.  
 
 
Figure 7. Fluorescent images of polyplex samples or immunostimulant alone after injection into HA gel at 





Figure 8. (A) Fluorescence intensity across the well was averaged from three measurements, normalized 
to a standard in each image, and then plotted. To calculate percent reduction, AUC of the middle of the well 





Figure 9. Normalized spatial plots and percent reduction graphs for polyanion alone controls.  
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Figure 10. Normalized spatial plots and percent reduction graphs for PLL+polyI:C polyplexes. 
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Figure 11. Normalized spatial plots and percent reduction graphs for PLL+CpG polyplexes. 
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Figure 12. TLR3 activation 8 hr (black) and 20 hr (grey) and cellular metabolism of polyplex (blue) and of 




Figure 13. TLR9 activation 8 hr (black) and 20 hr (grey) and cellular metabolism of polyplex (blue) and of 





Figure 14. Effect of PLL molecular weight and mass ratio on TLR activation. 
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Figure 15. Effect of PLL molecular weight and mass ratio on TLR activation HEK blue cell metabolism 
for (A) PLL+polyI:C and (B) PLL+CpG polyplexes. 
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7. Supplemental Materials 
 
Supplementary table 1. Mass ratio translation to molar ratio. 
 
 




Supplementary Figure 1. Concentration curve of polyI:C and CpG in their respective HEK blue reporter 
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The concept of cancer immunotherapy was proposed a century ago when Dr. William Coley first 
attempted to harness the body’s immune system to fight off cancer.1-2 While this approach seemed 
promising, manipulation of the immune response can be dangerous and therefore must be deliberately 
controlled. Scientists made significant progress in developing cancer immunotherapies as alternatives to 
traditional treatments such as chemotherapy and radiation. Currently approved cancer immunotherapies 
range from checkpoint inhibitor monoclonal antibodies (mAbs) that decrease tumor immune suppression, 
viral therapies that activate immune cells, and mAbs that label certain cell types for death.3 Unfortunately, 
current therapies often fail to evoke an immune response capable of overcoming the immunosuppressive 
tumor microenvironment while also exhibiting acceptable safety profiles.4-7 Additionally, checkpoint 
inhibitors are predominantly effective in tumors that are considered ‘hot’, tumors characterized by high 
infiltration of immune cells that express the target immune-dampening markers.8-9  In order to properly 
activate T cells for tumor killing, there must be expression of co-stimulatory molecules, secretion of 
proinflammatory cytokines, and presentation of antigens, all of which are suppressed in the tumor 
microenvironment.10-12  
 One method to overcome the suppressive tumor microenvironment is the use of immunostimulants, 
which are typically compounds that activate a proinflammatory, innate immune response. The use of 
immunostimulants in the presence of antigen causes a number of reactions including upregulation of co-
stimulatory molecules, increased antigen presentation, and secretion of proinflammatory cytokines, which 
can lead to the formation of tumor specific T-cells.10, 13-14 One class of immunostimulants, toll-like-receptor 
agonists, are capable of inducing a strong T cell response after binding to their respective toll-like receptors 
(TLRs). TLRs recognize bacterial and viral pathogen associated molecular patterns (PAMPs), which trigger 
specific signaling pathways. Two TLR agonists are currently FDA approved. Ceravarix™ is a cervical 
cancer vaccine that contains monophosphoryl lipid A (MPL), a TLR4 agonist in the adjuvant system.15 The 
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other, Aldara™, is a cream for superficial basal cell carcinoma, the main active ingredient is a TLR7/8 
agonist called imiquimod.16  
 Two vastly explored TLR agonists in cancer immunotherapy are polyinosinic:polycytidylic acid 
(polyI:C) and CpG, which are TLR3 and TLR9 agonists, respectively. Both compounds exhibit strong 
induction of interferons, leading to a proinflammatory environment after binding to TLRs, thus generating 
memory and tumor-specific T cells.17-19 Several clinical trials utilize TLR agonists alone or in combination 
with other anti-cancer therapies such as radiation or checkpoint inhibitors. PolyI:C is a double-stranded (ds) 
RNA mimic that has shown both antiviral and anticancer activity.20-21 Additionally, TLR3 agonists have 
demonstrated the ability to directly inhibit tumors in vitro by decreasing cell proliferation and inducing 
apoptotic cell death.20 To date, polyI:C therapy has not been successful in cancer patients because of dose-
limiting side effects.22 The side effects are reduced when polyI:C is mixed with poly-L-lysine in an 
experimental drug called Hiltonol.23 Another TLR agonist, CpG, is a short, single-stranded synthetic 
oligonucleotide that contains multiple, unmethylated cytosine-phosphate-guanine motifs, which mimic 
bacterial DNA. Since its discovery in 1994, CpG has been extensively evaluated in clinical trials for 
cancer.24 Unfortunately, no therapeutics containing CpG are currently approved. One company, Checkmate 
Pharmaceuticals, utilizes a modified version of CpG class-A that self assembles into G tetrads that stack to 
form G-quadruplexes.25 Despite the fact that PolyI:C and CpG are promising candidates for use in cancer 
immunotherapy, one vital challenge is determining how to properly deliver these agents to tumor tissue. 
While systemic delivery can target multiple tumor sites, full body exposure of immunostimulants 
can cause improper activation of the immune system in healthy tissue, generating harmful immune and 
autoimmune reactions.6 One possible solution to this dilemma has been termed human intratumoral 
immunotherapy (HIT-IT) with the aim of propagating anti-tumor responses at sites distal to the injection 
concurrently with shrinkage of treated tumors. This process, called the abscopal effect, can occur when 
tumor-activated immune cells drain to the lymph nodes and circulate to other parts of the body.26  Immune 
cells recruited to the site of stimulation and activated by the immunostimulant could ultimately present 
tumor antigen and activate tumor-specific T cells. From a drug delivery perspective, the immunostimulants 
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should to be retained at the tumor injection site and yet available for endocytosis by immune cells to reach 
endosomal TLR3 and TLR9. Since free polyI:C and CpG are both negatively charged, intracellular delivery 
is hindered by electrostatic repulsion due to the negatively charged cell membrane. In contrast, a net 
positively charged nanoparticle may allow for tumor retention, attraction to cell membranes, and increased 
intracellular delivery of the TLR agonists.27 Polyplex nanoparticles, which are complexes between 
polycations and polyanions, have been widely explored for gene delivery therapies since they can be 
modulated with specific size, charge, and loading capacity.28-31  
Previously, our lab has shown how glatiramer acetate (GA), a highly positively charged 
polypeptide, is effective in delivering plasmid DNA to cells.32 GA, otherwise known as Copaxone®, is an 
FDA-approved drug for relapsing-remitting multiple sclerosis. Specifically, GA is comprised of four amino 
acids in a random sequence with the following amino acid ratios: L-glutamic acid (0.14), L-alanine (0.43), 
L-tyrosine (0.09), and L-lysine (0.34) (Figure 1). It has an average molecular weight between 5,000 and 
9,000 Da, but can range anywhere from 2,500 to 20,000 Da.33 Although the mechanism of action is unclear, 
GA has limited systemic exposure and pronounced reactions at the site of injection. Previous works to 
characterize the mechanism of GA led to an understanding that GA persists at the site of injection and forms 
aggregates in situ.33 These aggregates appeared as spherical particles that could be seen associating with 
local connective tissue.33 Unlike other polycations utilized in polyplexes, studies have shown that GA 
persists at the injection site and potentially aids in activating an immune response.33  
In the current work, we aim to exploit the characteristics of positively-charged GA in order to 
deliver the negatively-charged immunostimulants as a polyplex nanoparticle. Moreover, due to the 
persistence of GA at the injection site, we hypothesized GA may recruit immune cells to the site of injection. 
Here, we study complexation between GA and either polyI:C or CpG and the relation to in vitro and in vivo 
efficacy. Various methods were employed to characterize the polyplexes including particle sizing, zeta 
potential, and experiments that elucidated the stability of the polyplexes. To evaluate retention, polyplexes 
were tested in an in vitro system to emulate transport in human tissue. In vitro assays were used to assess 
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the activity of the complexed TLR agonist. Finally, in vivo efficacy and immune responses were determined 
in a mouse tumor model of head and neck squamous cell carcinoma (HNSCC).   
2. Methods 
2.1 Polyplex formation 
20 mg/mL solutions of Copaxone® 1 mL pre-filled syringes from Teva Neuroscience, Inc. (Kansas City, 
MO) were donated by the University of Kansas Medical Center. Copaxone, or Glatiramer acetate will 
hereafter be referred to as GA. CpG ODN 1826 and LMW PolyI:C were purchased from Invivogen (San 
Diego, CA). GA polyplexes with CpG ODN 1826 or LMW PolyI:C were prepared by adding equal volumes 
of GA and CpG or PolyI:C diluted to the desired concentration followed by repeated pipetting for 30 
seconds. The polyplexes were then stored at room temperature for a minimum of 20 minutes before being 
analyzed to use in cell culture. Polyplexes were prepared at varying mass ratios of 1, 2, 3, 4, 5, 10, 20 that 
represent mass of GA divided by the complex partner, CpG or PolyI:C (Figure 2). Mass ratio was utilized 
rather than a polymer nitrogen to anion phosphate (N:P) ratio due to heterogeneity of the components. 
Polyplexes were made up in 4% mannitol except for the pH comparison in agarose gel and zeta potential 
measurements which used PBS and 1mM KCl.  
2.2 Agarose gel electrophoresis 
 Agarose was purchased from Sigma Aldrich (St. Louis, MO). Tris-acetate-EDTA (TAE) buffer was 
purchased from Invitrogen (Carlsbad, CA). CpG or PolyI:C polyplexes were prepared as described holding 
the CpG or PolyI:C concentration constant while varying the GA concentration. Then, 4 µL 6x DNA 
loading dye (Takara Bio Inc., Japan) was added to the polyplex (10 µL) before the solution was loaded onto 
a 3% agarose gel, and electrophoresed for 25 minutes at 100 V. CpG and PolyI:C alone were utillized as 
controls. A 1 kb DNA ladder (Promega, Madison, WI) was used as a general reference. The gel was stained 
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by shaking with SYBR Gold (Invitrogen, Carlsbad, CA) in TAE buffer for 25 minutes at room temperature. 
Then, the gel was imaged on AlphaImager (Protein Simple, San Jose, CA). 
2.3 Particle sizing and zeta potential 
 The effective radius (nm) of CpG or PolyI:C polyplexes was determined by dynamic light scattering 
(DynaPro, Wyatt Technology, Santa Barbara, CA). Samples for particle sizing were prepared in 4% 
mannitol (Sigma Aldrich, St. Louis, MO). Measurements were conducted after a 20 minute incubation time 
at room temperature. Zeta potential measurements were measured by Zeta PALS (Brookhaven Instruments, 
Holtsville, NY). All samples for zeta potential measurements were prepared in 4% mannitol and diluted 
into 1 mM KCl for analysis.  
2.4 Rhodamine labeled GA 
Copaxone® in pre-filled syringes was first dialyzed against DI water to remove the mannitol buffer.  It was 
then reacted with 2 equivalents of Rhodamine B N-hydroxysuccinimide (NHS) ester in CPB buffer (10mM 
citrate, 20mM phosphate, 40mM borate) pH 7.5 with 20 % dimethyl sulfoxide (DMSO). The reaction was 
protected from light and allowed to react at room temperature for 4 hours with gentle agitation. To separate 
labeled drug from excess dye, the reaction mixture was placed into 2 kDa MWCO dialysis cassettes and 
dialyzed against 5% dimethylformamide (DMF) in water at pH 2, followed by 0.5 M LiCl solution, and 
finally DI water. Dialysis was performed sequentially in each buffer for 24 hours with one buffer change 
in between for total of 72 hours. The resulting reaction solution was characterized by HPLC and lyophilized. 
7000 Da was used as the approximate molecular weight (MW) of Copaxone®. The conjugation of dye 
labeled onto GA was determined by constructing a calibration curve based on the fluorescence of 
Rhodamine B NHS ester at various concentrations and comparing the fluorescence of the labeled product 
to the calibration curve. The fluorescence experiments were performed using Synergy™ H4 Microplate 
Reader (BioTek, Winooski, VT) with 540/25 nm excitation filter and 620/40 nm emission filter. 
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2.5 Fluorescence polarization 
Fluorescence polarization measurements were taken on Synergy H4 microplate reader (BioTek, Winooski, 
VT). Rhodamine labeled GA was complexed with varying amounts of CpG or PolyI:C as previously 
described. Standard curves for Rhod-GA, CpG, and PolyI:C were prepared. Then, 200 µL of the polyplexes, 
or standards were added to a 96 well, black microplate (Corning, Corning, NY). Using fluorescence 
polarization settings on the plate reader, the excitation filter was set to 485 nm/ 20 nm and emission filter 
to 620 nm/ 40 nm. To calculate the polarization, first the parallel and perpendicular values for the standards 
(CpG or PolyI:C alone) are subtracted from their respective polyplexes. Then polarization was calculated 
using the following equation: 𝑃𝑃 = 𝐼𝐼∥−𝐼𝐼⊥
𝐼𝐼∥+𝐼𝐼⊥
.  
2.6 Transmission electron microscopy (TEM) 
TEM images were captured using FEI Tecnai F20 XT Field Emission Transmission Electron Microscope 
at the University of Kansas Microscopy and Analytical Imaging Laboratory. Polyplexes or individual 
components were added to carbon coated grids and touched on a Kimwipe to remove excess liquid, then 
immediately dipped into liquid nitrogen prior to imaging.  
2.7 Assessment of DNA/RNA accessibility by SYBR gold assay 
The degree of accessibility of the DNA or RNA following complexation with GA was assessed by the 
staining of SYBR Gold to accessible DNA or RNA. Polyplexes were made as described above and after 20 
minutes polyplexes were added to a 96-well plate in triplicate followed by SYBR gold stain and mixed 
well. After approximately 5 minutes the fluorescence was measured using a Synergy H4 microplate reader 
(BioTek, Winooski, VT). The excitation filter was set to 495 nm and emission filter to 537 nm. 
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2.8 The effect of dextran sulfate on the stability of the polyplexes 
The effect of dextran sulfate on the stability of the polyplexes was assessed by observing the change in 
fluorescence of SYBR Gold upon increasing amounts of dextran sulfate. 90 uL of each polyplex was added 
to a 96-well plate followed by 10 uL of various concentrations of dextran sulfate and mixed well. After 20-
30 minutes of RT incubation, 11 uL of 10x SYBR Gold was added and 5 minutes later the plate was 
analyzed as described previously.  
2.9 Hyaluronic acid gel retention 
To test the polyplexes ability to retain at an injection site, we devised a model system to emulate transport 
in human tissue made of highly viscous hyaluronic acid (HA) to which we could inject labeled polyplexes 
in the center and observe the dispersion over time. 0.8-1.5 MDa HA was added to PBS buffer at 20 mg/mL 
then placed on end-over-end rotator overnight to dissolve. The HA gel was then weighed out into a 96 well 
black plate at 0.28 g/well. The plate was centrifuged to remove bubbles then placed at 4 ˚C until use. 
Polyplexes were prepared as described but for this test they were first made up in 90% of the total volume, 
let incubate for 20 minutes, then 10% of the total volume of 20x SYBR Gold stain was added for an 
additional 5 minutes. A 3D printed device was designed to allow uniform injection into the wells at half the 
depth of the gel. 7 µL of sample was injected through the device into the center of the well using reverse 
pipetting. Fluorescent images were obtained at varying time points on a MaestroFlex Imager (Cambridge 
Research and Instrumentation, Woburn, MA). Wells were analyzed using ImageJ software. Fluorescence 
intensity was measured across the well at 3 different angles (rotated 60˚ each) and averaged to create a 
spatial intensity plot (figure 8A). The values were then normalized to a standard that was constant in every 
image. Area under the curve from pixels 15-25 was used to calculate the percent intensity reduction from 
time 0.  
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2.10 Jaws II cells 
Jaws II cells (ATCC Manassas, VA) were cultured in RPMI, 10% FBS (Atlanta Biologicals), 1% penicillin-
streptomycin (P/S, MP Biomedicals), and 5 ng/mL GM-CSF (Tonbo Biosciences). Jaws II cells were plated 
at 2.5x105 cells/well, at 270 µL/well in a 96 well plate and allowed to adhere for an hour before adding 
treatments. Then, 30 µL of 10x polyplex or GA, polyI:C, or CpG was added to each well. Additionally to 
assess cell stability in the presence of various buffers, 30 µL of either 4% mannitol, 5% glucose, nuclease-
free water (NFW), or saline was added to the well and images were taken on an inverted microscope (Accu-
Scope, Hicksville, NY). Additionally, a resazurin assay was utilized to assess cell metabolism.  
2.11 Bone marrow derived dendritic cells (BMDCs) 
Five-week-old C57BL/6J mice were purchased from Jackson Laboratories and housed under specified, 
pathogen-free conditions at The University of Kansas. All protocols involving mice were approved by the 
Institutional Animal Care and Use Committee at The University of Kansas. Mice were sacrificed and their 
femurs were collected. The ends of the femur were clipped, and the bone marrow was flushed out using a 
21-gauge needle attached to a 5 mL syringe containing RPMI supplemented with 1% penicillin-
streptomycin. Cells were collected and centrifuged for 7 minutes at 1,350 rpm at 4℃. The supernatant was 
removed, replaced with red cell lysis buffer, and incubated at room temperature for 10 minutes. Lysis was 
stopped with 6x volume of cold complete medium (RPMI, 10% FBS, 1% penicillin-streptomycin). The cell 
solution was passed through a 70 µm nylon cell strainer and centrifuged for 5 minutes at 1,700 rpm and 
4℃. The supernatant was removed and replaced with complete medium, and cells were plated at 
approximately 2x106 cells per T-75 culture flask in 12 mL complete medium spiked with 20 ng/mL GM-
CSF. On day 3, the medium was removed to discard any floating cells, and 12 mL of media with fresh GM-
CSF was added to the cells. On day 8, the media with cells were collected and the bottom of the flask was 
thoroughly rinsed to collect any loosely adherent cells. BMDCs were then plated at 2.5x105 cells/well and 
treated as previously described for the Jaws II culture conditions. Cell viability was inferred from metabolic 
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activity measured by the resazurin assay. Wells were washed and 100 µL of RPMI and 20 µL of 0.01% 
resazurin were added to the wells. Plates were incubated at 37°C for one or two hours, and the fluorescence 
was measured at ex/em 560/590 nm using a Synergy H4 microplate reader (BioTek, Winooski, VT). Data 
within each stimulation group was normalized to the untreated media control at their respective time points. 
TNF-α ELISA. TNF-α expression by the dendritic cells was measured by ELISA (R&D systems, 
Minneapolis, MN) as per manufacturer instructions.  
2.12 In vitro HEK blue reporter cell assay  
HEK-Blue TLR9, TLR3, and Null cell lines (Invivogen, California) were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Corning, NY) supplemented with 10% FBS, 1% penicillin-streptomycin, and 
the selective antibiotics according to the manufacturer’s protocol. HEK-Blue TLR cells allow for the study 
of TLR activation by observing the stimulation of secreted embryonic alkaline phosphatase (SEAP), a 
protein associated with downstream activation of TLRs. At 50-80% confluency, cells were harvested and 
resuspended in HEK detection media (Invivogen, California) and 180 uL was seeded into 96-well plates at 
~8x105 cells/well. 20 uL of polyplexes or controls were added to respective wells and the plate was 
incubated at 37 °C, 5% CO2 for at least 6 hours or until color change. Absorbance readings were measured 
at 640 nm. Null cells were used as the control. Working polyanion concentrations were determined by 
selecting a concentration that achieved a reasonable response factor as shown from a concentration curve 
completed in the respective cell lines (supplementary figure 1). PolyI:C was held constant at 200 µg/mL 
and CpG was at 100 µg/mL. Cells and sample were incubated with the HEK blue detection media for TLR 
activation measurements or in regular media for metabolism evaluation in resazurin assays. 
2.13 AT84 cells 
AT84 cells were derived from a spontaneous squamous cell carcinoma in the oral mucosa of a C3H 
mouse (Hier/Karp 1995, Paolini/Venuti 2013) and were gifted by Aldo Venuti (Regina Elena National 
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Cancer Institute, Rome, Italy). Cells tested negative for interspecies contamination (species: mouse(+), 
rat(-), human(-), Chinese hamster(-), African green monkey(-); Idexx BioResearch), negative for rodent 
pathogens (Idexx BioResearch, 21 pathogen IMPACT I PCR profile), and negative for Mycoplasm 
contamination prior to animal studies (Lonza, Basel, Switzerland, MycoAlert test kit). Idexx CellCheck 
STR (short tandem repeat) profile: MCA-4-2: 20.3, 21.3; MCA-5-5: 15; MCA-6-4: 18, 19; MCA-6-7: 12; 
MCA-9-2: 15; MCA-12-1: 16; MCA-15-3: 25.3, 26.3; MCA-18-3: 16; MCA-X-1: 26, 27. Cells were 
cultured in RPMI-1640 media (Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% 
FBS (Corning Corning, NY), and 100 U/mL penicillin / 100 µg/mL streptomycin (HyClone, Thermo 
Fisher Scientific, Waltham, MA) in a humidified incubator at 37°C and 5% CO2.  
All rodent studies were done at the University of Kansas Animal Care Unit, which is in compliance with 
the “Guide for the Care and Use of Laboratory Animals” and is accredited by the Association for the 
Assessment and Accreditation of Laboratory Animal Care International (AAALAC). The studies were done 
according to a protocol approved by the University of Kansas IACUC committee.  
2.14 Immuno-competent tumor model for efficacy  
CpG polyplexes displayed better TLR activation and retention potential over polyI:C polyplexes so CpG 
polyplexes were selected to move forward in tumor studies. Wildtype C3H mice (Charles River Strain 025, 
6-8 weeks old, 20-25g) were used for in vivo tumor studies. Both male and female mice were used in the 
studies. Since no differences were found between the sexes, results combined both sexes into one group. 
Mice were anesthetized using 5% isoflurane in O2 for 5 minutes. One million AT84 cells in 50 µl PBS were 
injected subcutaneous (s.c.) into the floor of the mouth via an extra-oral route of C3H mice to obtain 
orthotopic allograft tumors (Hier/Karp 1995, Paolini/Venuti 2013). Treatment began when tumors reached 
~100 mm3, generally days 10-12 days after cell injection. Under isoflurane anesthesia, mice were treated 
intratumorally with 75 µg (based on immunostimulant) in 50 µL sterile 4% mannitol every three days for 
5 total treatments. Serum was collected via retroorbital bleeding 2 hours after the first and fifth injections. 
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Serum cytokines were measured using a U-PLEX kit (Meso scale Diagnostics, LLC, Rockville, MD) as per 
the manufacturer instructions. Animal survival was evaluated, however, in this model, death was usually 
caused by a tumor size large enough to impede regular mobility. Tumor size was monitored twice per week 
and calculated: tumor volume (mm3) = 0.52 × (width)2 × length, where length is the longer of two 
perpendicular dimensions. Statistical comparisons were done using GraphPad Prism software. On day 36 
when all vehicle-treated tumors reached the maximum allowable size (1800 mm3), all animals were 
sacrificed, and tumors extracted.  Tumor was bisected, and one half was frozen in OTC media (Fisher 
Scientific) for cryosectioning and staining.  The other half was cut into small pieces (< 5 mm) and stored 
in RNA Later solution (Ambion, Inc. Austin, TX). For cryosectioning slices, the sections were fixed in 10% 
formalin, blocked with 5% goat serum in PBS, and stained with primary antibodies. Primary antibodies 
were diluted to 5 µg/mL in blocking buffer (5% goat serum in PBS) and incubated overnight at 4 °C. 
Antibodies used were Alexa Fluor ® 488 anti-CD8a, Alexa Fluor® 594 anti-CD11b, and Alexa Fluor® 
647 anti-CD11c (BioLegend). After antibody staining, sections were stained with Hoechst 33342 and 
mounted in SouthernBiotech™ Fluoromount-G™ Slide Mounting Medium (SouthernBioTech, 
Birmingham, AL) and stored in the dark at 4 °C. Images were acquired using an Olympus IX-81 inverted 
epifluorescence microscope at 10x magnification. The acquired images were compiled on Slidebook 6.0. 
3. Results 
3.1 Polyplex formation 
  Agarose gel electrophoresis studies were used to visually test the ability of the GA to polyplex with 
the polyanions (polyI:C and CpG). Specifically, free, negatively charged polyI:C or CpG migrated through 
the agarose gel whereas positively charged GA did not. When polyI:C or CpG are complexed with GA, the 
material is retained in the loading well. In the higher pH buffer (Figure 3A and C), more GA (a higher 
mass ratio) was required to fully immobilize the polyanion. The GA immobilized polyI:C at lower mass 
ratios than CpG but this can be attributed to molecular weight differences of the polyanions. Differences in 
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complexation as a function of pH were observed with both polyI:C and CpG. In particular, polyI:C was 
fully immobilized at R5 at pH 7 and R2 at pH 5.  A similar trend was seen with CpG polyplexes where 
immobilization occured at R10 and R4 for pH 7 and pH 5, respectively. In more acidic conditions, the 
nitrogens on GA become more protonated, requiring less GA to immobilize the polyanionic TLR agonists.  
3.2 Polyplex characterization 
Zeta potential measurements (Figure 4A-B) agreed with electrophoresis studies, showing a transition 
to net positive charge at the same mass ratio where the polyanion was immobilized on agarose gels. At pH 
7, both polyI:C and CpG polyplexes required a higher GA ratio to achieve a net positive charge than at pH 
5. At the lowest ratio, the pH did not significantly impact the zeta potential. At higher ratios, the charge 
started to plateau, indicating an excess of GA. At lower ratios, the negative zeta potential could be a result 
of free polyanion in solution or rather the polyanion exposed on the surface of the polyplex whereas at 
higher ratios the polyanions are encapsulated within the polyplex. These results exhibited the ability to 
control the surface charge with pH and ratio. For all polyplexes the radius was between 20 and 70 nm, or a 
diameter range of 40-140 nm (Figure 4C-D). For polyI:C and CpG, the polyplexes were net positively 
charged when the ratio is R2 and R5, respectively in 4% mannitol buffer (pH 5), which is the diluent used 
for GA in the product Copaxone®. To corroborate particle sizing data, TEM images were collected and the 
results correlated with the particle sizes determined by DLS measurements (Figure 5). With controls alone, 
spherical particles were not observed, but in the polyplex samples, spherical particles were detected within 
the expected size range.  
3.3 Immunostimulant accessibility characterization 
Fluorescence polarization is typically utilized to quantify the associations between a protein and a 
ligand, however, this technique can also be used to analyze binding of fluorescent molecules and a protein. 
Here, fluorescence polarization was utilized to monitor complexation of fluorescently labeled-GA to 
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polyI:C or CpG. In the assay, samples were first subjected to polarized light. If the fluorescent molecule is 
free in solution, it will emit de-polarized light. Conversely, when it is bound and its mobility is decreased, 
the emitted light remains polarized, resulting in an increase in polarization. Rhodamine-labeled GA and the 
polyanion were mixed at various ratios holding the Rhodamine-GA constant and changing the concentration 
of polyI:C or CpG. The data collected complimented the agarose gel and zeta potential data. Specifically, 
the increase in polarization plateaued at the same mass ratio in which the net charge was positive and gel 
electrophoresis indicated immobilization (Figure 6).  
The accessibility of polyI:C or CpG within the polyplexes was assessed by staining with SYBR 
Gold (Figure 7A-B). Free polyanion is more accessible for stain whereas complexed polyanion is more 
encapsulated and inaccessible. As expected, fluorescence decreased as the mass ratio increased indicating 
that the polyanion was becoming more encapsulated in the polyplex. Interestingly, the polyI:C control 
sample did not have the highest level of fluorescence compared to the polyplexes which was expected (and 
seen with the CpG group). One possible explanation is that GA may be rearranging or displaying the polyI:C 
on the surface rather than encapsulating it at the smaller mass ratios. To assess the interaction strength of 
the polyplexes, dextran sulfate was titrated into polyplex samples. Fluorescence measurements were 
obtained after incubation with increasing amounts of dextran sulfate for each polyplex tested and the signal 
was normalized to the signal at 0 dextran sulfate for the same polyplex (Figure 7C-D). For higher mass 
ratios, fluorescence increased with increasing dextran sulfate. At lower ratios, no trend was evident 
suggesting free polyanion dominated the fluorescence emitted. Additionally, polyI:C polyplexes had a 
larger fold increase in fluorescence with increasing dextran sulfate than CpG polyplexes suggesting a 
weaker interaction strength.  
3.4 Hyaluronic acid gel retention  
To simulate tumor tissue transport, polyplexes were injected into a model system to emulate transport 
in human tissue. HA is one of the main components within the extracellular network and high molecular 
weight HA has been used to simulate subcutaneous (SC) space injection.34-35 For SC injection simulation, 
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10 mg/mL HA was previously reported35, thus to model a denser tumor environment, the concentration was 
increased to 20 mg/mL. Figure 8C are representative examples some of the samples in this experiment 
over 0, 2, and 5 hour time points- where the greatest differences were observed. Normalized spatial plots 
are provided in figure 8D. Free polyI:C and CpG diffused quickly. Interestingly, the polyI:C polyplexes 
also appeared to diffuse quickly, even at higher ratios of polycation in comparison to CpG polyplexes. 
While the ratios cannot be directly compared between polyI:C and CpG polyplexes due to MW differences, 
the zeta potential and agarose gel profiles are similar. For the higher ratio CpG polyplexes, a peak in the 
center could still be observed at 24 hours and a clear, non-diffused spot was still seen but not imaged out 
to 72 hours. Since the polyplexes were labeled using SYBR Gold stain, each polyplex stained differently 
depending on the accessibility of the polyI:C or CpG. To make the samples directly comparable, data were 
normalized to the fluorescence intensity at time zero (Figure 8A-B). PolyI:C polyplexes diffused faster and 
were less dependent on ratio at the time points measured, but never diffused as quickly as the polyI:C 
control. CpG polyplex retention at the injection site was dependent on the ratio with polyplexes made using 
more GA persisting longer.  
3.5 Dendritic cell metabolism 
In an effort to determine an optimal buffer for polyplex formulation, cellular metabolism data and 
microscopy images of Jaws II dendritic cells were acquired after incubation with various buffers 
including nuclease free water, glucose, mannitol, PBS, and NaCl (supplementary figure 2). Glucose was 
the only buffer that showed detrimental effect on the cells.  Next, to evaluate cytotoxicity in dendritic 
cells, cellular metabolism was measured after individual component or polyplex incubation with either 
Jaws II cells or BMDCs at two concentrations (supplementary figure 3). For the controls, GA, polyI:C, 
and CpG, no significant toxicity was observed however the metabolism was increased in BMDCs as 
compared to Jaws II DCs, particularly for CpG. Polyplexes showed a similar trend where BMDCs were 
more effected. CpG polyplexes impact on cellular metabolism was not effected by ratio whereas polyI:C 
polyplexes showed decreased metabolism with increased ratio. Further, for select samples, TNFα 
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secretion was measured from cell culture supernatant (supplementary figure 4). CpG polyplexes had a 
significant impact on BMDCs when polyI:C polyplexes did not and the opposite trend was true for 
incubation with Jaws II DCs. This could be a result of levels of toll-like receptors in the different cell 
types.36 
3.6 In vitro HEK blue reporter cell assay 
PolyI:C and CpG are TLR agonists of TLR3 and TLR9, respectively. HEK blue hTLR reporter cells 
were used to examine the effect of complexation on TLR activation. TLR activation was normalized to the 
respective polyanion control. An increased mass ratio of GA:CpG resulted in decreased TLR activation 
(Figure 9). Interestingly, some of the CpG polyplexes were up to twice as effective at activating TLR9 as 
the CpG alone. The trend was less pronounced for polyI:C polyplexes, but still showed the lowest TLR 
activation at the highest ratio. Generally, the polyI:C polyplexes activated TLR3 similar to free polyI:C 
with the exception of a GA:polyI:C ratio of 20. TLR activation did not seem to be affected by the differences 
in cellular metabolism (Figure 10). There was a slight decrease in metabolism as the ratio increased which 
was more pronounced at 20 hours but overall there were few significant differences compared to the 
untreated control.  
3.7 Tumor studies in mice 
CpG polyplexes were evaluated in a mouse tumor model of head and neck squamous cell carcinoma. 
Mice were inoculated with 1x106 AT84 cells into the floor of the mouth. IT injections were administered 
every 3 days for a total of five injection and began when tumors reached ~100 mm3 (Figure 11A). 
Treatment groups included CpG, CpG polyplexes at two mass ratios (R4 and R6), GA low and GA high 
corresponding to the GA dose delivered for R4 and R6, and the 4% mannitol vehicle control. The injection 
volume was consistent and CpG concentration was constant in all CpG containing treatments. The 
polyplexes as well as CpG alone had 100% survival whereas the controls, mannitol, and both GA 
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concentrations had 50% or less survival (Figure 11C). The separation was also clear in the tumor burden 
data with the control groups having tumors almost twice as large as those treated with polyplexes or CpG 
alone at the end of the study (Figure 11B). At the completion of the study, tumors were resected, 
cryosectioned, and stained for markers of immune cells. Tumor slice staining revealed differences in 
CD11b, a marker for many types of immune cells (monocytes, granulocytes, macrophages, dendritic cells, 
NK cells, and some T and B cells), and CD11c, a marker for dendritic cells (Figure 13-14). Polyplexes and 
CpG groups induced the infiltration of CD11b and CD11c immune cells into the tumor compared to the 
controls. While not statistically significant, R6 appeared to have some increased CD8a (cytotoxic T 
lymphocyte) infiltration. Further, GA-Hi appeared to have some enhancement of CD11b and CD11c but 
was not statistically different than the control. Images of the staining indicated that the infiltrating immune 
cells remained mostly in the periphery of the tumor (Figure 13).  
3.8 Serum cytokines 
To evaluate the systemic effect of the IT treatments, cytokine levels from serum taken two hours after 
the first and fifth injections were determined (Figure 15). CpG treatment induced the greatest level of 
cytokines across the panel in all but IL-2 after the fifth injection where R4 and R6 were higher. CpG, R4, 
and R6 produced significantly greater cytokine levels compared to both mannitol and GA groups for the 
majority of cytokines. CpG was always significantly higher. R6 treatment showed increased cytokine 
production compared to R4 in all cytokines.  
4. Discussion 
Intratumoral injection of immunostimulants has the potential to induce immunity to local and distal 
tumor tissue and to work synergistically with checkpoint inhibitors. Immunostimulant transport out of the 
tumor and into systemic circulation requires attention. High incidences of AEs in recent clinical trials have 
highlighted the necessity to optimize delivery of immunostimulants to decrease systemic toxicity.37-38 In 
order to achieve HIT-IT of immunostimulants without systemic toxicity, retention and activity of the 
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therapy at the site of injection is a critical parameter.39-40 Immunostimulants such as PAMPs may traffic 
into systemic circulation after IT injection, however, studies have shown dramatic benefits to depots, slow 
release, and particulate formulations of PAMPs to increase tumor retention and local activity.30, 37, 39-41 
Furthermore, many approaches aimed at increased immune activation have seen slightly enhanced safety 
and efficacy profiles when using structurally modified immunostimulants or emulsion or complex 
formulations.23, 25, 42-45 Specifically, packaging of immunostimulants into condensed particles has been 
found to have a positive effect on retention and innate immune activation over the unformulated active 
ingredient.30, 39 
The packaging of DNA or RNA by polycations into a net positively charged particle has been 
frequently used for intracellular delivery46-49, but this work introduces a new perspective that these 
polyplexes can also aid in tumor retention. Common polycations used for delivery have a history of toxicity 
problems, especially at higher molecular weights30-31, 50-53, therefore utilization of a polycation that already 
has an approved safety profile is attractive. An already FDA approved and polycationic drug, glatiramer 
acetate (GA), is a potential delivery tool when formulated with TLR agonists, polyI:C or CpG. Based on 
the characteristics of GA33, the resulting cationic polyplex particles was hypothesized to promote cellular 
uptake and promote injection site retention.  
Major factors contributing to tissue transport and immune activation are hydrodynamic radius and 
charge.39, 54 Depending on the route of administration, particles 10-70 nm tend to drain to lymph nodes and 
>70 nm tend to form depots at the injection site.54-60 Furthermore, positively charged particles below 500 
nm have been seen to be optimal for APC uptake.31, 54-55, 61 Previous studies of IT injection reported cationic 
liposomes and particles 120 – 250 nm were retained at the injection site whereas neutral and smaller 
liposomes drained from the tumor.62-63 DLS measurements of the GA polyplexes yielded particle diameters 
of 40 nm – 140 nm, suggesting these could retain at injection site, or localize to draining lymph nodes, and 
attract the attention of APCs. Similar to previous reports, the particle size did not vary significantly with 
changing of the mass ratio.64 Further, the polyplexes can be tuned to achieve a net positive charge, which 
is important for increased cell uptake as it can enhance the attractive force towards the negatively charged 
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cell surface. Positive charge has been shown to be specifically significant for injection site retention33 
including tumor62-63 retention via electrostatic interactions.  
GA polyplexes enhanced TLR activation compared to free immunostimulant suggesting particle 
formation promoted cell uptake. Others have shown particle formation is critical for enhanced APC 
uptake.39, 56, 65 While most pronounced with the CpG polyplexes, TLR activation decreased as the ratio 
increased. Others found a similar correlation of TLR agonist accessibility within a polyplex and the 
corresponding receptor activation.66 Immunostimulant accessibility studies revealed an increasing 
polycation:CpG ratio rendered the immunostimulant less accessible suggesting an intermediate ratio may 
promote release and TLR engagement. While increased ratio may result in promotion of endocytosis into 
cells due to increased positive charge attracting the polyplex to the cell surface, the tighter binding causes 
a decrease in TLR agonist availability. Optimization of a polyplex for immunostimulant delivery would 
involve finding a “sweet spot”, or a ratio that favors efficient internalization but also an interaction strength 
that allows release or availability of the agonist within the cell. 
 Notably, the CpG polyplexes produced similar trends between accessibility and TLR activation 
whereas TLR activation induced by polyI:C polyplexes did not reflect its accessibility trends. This suggests 
that polyI:C may have a weaker association with GA than CpG. In fact, TLR agonist accessibility evaluated 
after challenge with a competing charged molecule revealed that fully immobilized polyI:C polyplexes 
were quicker to release the immunostimulant over CpG polyplexes at the same ratios indicating a weaker 
polyplex interaction strength. Therefore, a possible explanation for the TLR activation trend of polyI:C 
polyplexes could be disassociation of the polyplexes in cell culture media resulting in activation similar to 
polyI:C alone. Previous studies have indicated that dsRNA resists condensation compared to DNA which 
could explain the differences in interaction strength and TLR agonist accessibility.67-68 Overall, this data 
tells us that the polyplex interaction strength and TLR agonist accessibility are both important for TLR 
activation but are not necessarily directly related. 
Model tissue retention studies provided evidence that net positively charged polyplexes could 
remain at the injection site longer than immunostimulant alone. Because of HA’s negative charge, we 
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hypothesized that our net positively charged polyplexes would retain in the center of the well longer than 
polyI:C or CpG alone. These studies indicated that polyI:C polyplexes may have a weaker interaction 
strength than CpG polyplexes at the same mass ratio, a conclusion also drawn from the accessibility studies. 
Both polyI:C and CpG polyplexes showed increased retention with increase in ratio but CpG polyplexes 
displayed more pronounced retention capabilities. Taken together, while GA is able to condense both 
polyI:C and CpG into net positively charged particles, CpG polyplexes appeared to have a greater benefit 
to TLR activation and retention over polyI:C polyplexes.  
CpG polyplexes were studied in an immunocompetent tumor model of HNSCC. Polyplexes and 
CpG showed highly significant and similar efficacy over mannitol and GA controls. Interestingly, the CpG 
alone exhibited the smallest tumor size. Evaluation of tumor infiltrating immune cells showed that 
polyplexes and CpG were able to induce immune cell migration into tumor in comparison to controls. 
Interestingly, the immune cells were mainly located around the periphery with minimal staining towards 
the center. This could likely be a result of lack of vasculature penetrating the tumor tissue.  One theory to 
explain the differences in efficacy and immune infiltration seen with CpG alone over polyplexes could be 
that the availability of the CpG within the polyplex is effectively limiting the dose in vivo. However, while 
there may be slightly decreased efficacy, the increase in safety could mean the difference in being able to 
apply the immunostimulant in immunotherapy. Further work to understand the required potency and how 
complexation effects it would be needed. 
While CpG alone did appear to have the greatest effect on tumor burden, the survival and tumor 
burden information do not account for potential systemic exposure and safety concerns. The free, 
unformulated CpG produced significantly greater systemic cytokines related to toxicity. Specifically, 
cytokine release syndrome (CRS), whose symptoms are frequently seen in clinical trials of 
immunotherapies, is associated with elevated levels of IL-6, IL-10, TNFα, and IFNγ.37, 69 The elevated 
serum cytokines seen in treatment with CpG alone suggested that the polyplexes were retained at the 
injection site better than CpG alone. Previous studies examined CRS associated cytokines after CAR-T cell 
infusion immunotherapy. Patients exhibiting high grade CRS produced IL-6 that remained elevated whereas 
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IFNγ and IL-10 produced a more transient increase.70-71 In this work, IFNγ and IL-2 levels in R4 and R6 
increased between injection one and five whereas CpG did to a lesser degree. Along the same lines, for IL-
12 and GM-CSF, R4 and R6 increase and CpG decreases between injection one and five. Overall, levels of 
IL-10, IFNγ, and IL-2 increase from injection one to injection five whereas IL-23 and IL-17 decrease. These 
trends may be useful in understanding the kinetics of cytokine induction after immunostimulant therapy but 
more time points would be needed to establish plausible kinetics. 
5. Conclusion 
Immunostimulants are potent tools in immunotherapeutic treatment of tumors, however, even in IT 
administration, systemic toxicity issues are of concern. Our studies found that FDA approved GA can 
complex with TLR agonist immunostimulants polyI:C and CpG. These polyplexes mitigated systemic 
markers of toxicity in comparison to free TLR agonists, demonstrating increased retention. TLR activation 
and diffusion in model tumor tissue were highly dependent on the TLR agonist accessibility and particle 
properties, which can be tuned by altering the ratio of GA to the TLR agonist polyanion. While GA formed 
a polyplex particle with both polyI:C and CpG, CpG polyplexes exhibited higher retention at the simulated 
injection site and enhanced TLR activation capabilities. These results demonstrate the importance of 
particle characteristics in terms of efficacy and retention ability. Particle formation and immobilization of 
immunostimulant are not the only requirements for subsequent TLR activation or retention; interaction 
strength of the polyplex plays a significant role. This work displayed a novel method of delivering 
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 While traditional cancer treatments like radiation and chemotherapy directly kill cancer 
cells, cancer immunotherapy trains the body to fight its own cancer and can create lasting 
immune responses. Immunotherapy approaches aim to overcome the immune suppression 
established by the tumor microenvironment by activating an innate immune response. Activation 
of an innate immune response can be accomplished by delivering PAMPs, cytokines, viruses, 
targeted mAbs, or autologous engineered immune cells. For most immunostimulant therapies, 
the activation is non-specific therefore, immunostimulants should be delivered in the presence of 
tumor antigen so as not to cause improper immune activation towards healthy tissue. 
Furthermore, the use of local immunostimulants can induce the infiltration of immune cells into 
the tumor therefore increasing the efficacy of therapies like anti- PD-1 or anti-PD-L1 checkpoint 
inhibitors whose activity is dependent on interactions between tumor cells and immune cells. 
Traditional, systemic administration of immunostimulants has generated adverse events 
associated with systemic toxicity which are most commonly flu like symptoms or symptoms 
related to cytokine release syndrome (CRS). Local delivery can circumvent trafficking barriers 
and should reduce the systemic toxicity seen with systemic administration, however, clinical 
trials with intratumoral immunostimulants indicate that local delivery itself is not enough to 
prevent systemic toxicity events. Diffusion, or trafficking out of the tumor injection site and into 
systemic circulation can lead to similar adverse events seen with systemic administration. Many 
approaches have focused on modifications of therapy or formulations that have led to increased 
efficacy after IT injection, but few have directed strategies at increasing retention at the injection 
site.  
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 Chapter 1, reviewed the intratumoral cancer therapies currently in human clinical trials 
with discussions on the effects of therapy and formulation characteristics on the safety and 
efficacy. While it was difficult to make correlations, it was concluded that therapies with 
modified active or therapies formulated into a particle or emulsion tended to have better safety 
profiles presumably because of increased retention after injection.  
 This dissertation focuses on delivery strategies for two negatively charged TLR agonists 
polyI:C and CpG which are highly explored as immunostimulants in cancer immunotherapy. 
Both compounds exhibit strong induction of interferons, leading to a proinflammatory 
environment after binding to TLRs, thus generating memory and tumor-specific T cells.1-3 
PolyI:C is a double-stranded (ds) RNA mimic and TLR3 agonist that has shown both antiviral 
and anticancer activity.4-5 CpG is a short, single-stranded synthetic oligonucleotide and TLR9 
agonist that contains multiple, unmethylated cytosine-phosphate-guanine motifs, which mimic 
bacterial DNA.6 Notably, both polyI:C and CpG are agonists to an intracellular TLR and 
therefore require endocytosis. To achieve both goals of increased retention and intracellular 
delivery, polycations were selected as a delivery tool. Polycations have historically been 
employed for intracellular delivery of nucleic acid material7-10 and this work suggests that 
electrostatics can aid in injection site retention through interactions with highly negatively 
charged extracellular matrix (ECM).  
Chapter 2 explored the use of poly-L-lysine (PLL) as a polycationic delivery vehicle for 
negatively charged immunostimulants polyI:C and CpG to aid in injection site retention and for 
minimized systemic exposure. We evaluated polyplexes of the polycation PLL with polyanionic 
TLR agonists. Specifically, the relationship between PLL molecular weight and complex 
formation, TLR activation, and retention in a simulated tumor microenvironment was explored. 
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TLR activation was largely driven by the MW of PLL followed by the accessibility of the 
immunostimulant within the polyplex. Retention was also driven by these factors but in an opposite 
manner. Taken together, there is likely an optimal window of polycation MW and ratio that favors 
TLR activation and retention without causing toxicity. For CpG polyplexes, K9 through K50 was 
ideal for limiting cytotoxicity but higher MW was best for retention. Furthermore, this work 
supported with the hypothesis that particle formation is critical for immune activation and 
retention.11 These findings illustrate the potential use of polycations for carrier vehicles that not 
only aid in intracellular delivery but also contribute to injection site retention. The characterization 
results in this work suggest that PLL + CpG polyplexes may be a good candidate for increased 
intracellular delivery and decreased transport away from the tumor.  
 Chapter 3 developed and researched the novel idea of using an FDA approved, and safe 
drug called Glatiramer Acetate (GA) or Copaxone® as a delivery tool for negatively charged 
immunostimulants polyI:C and CpG. The studies found that GA can complex with TLR agonist 
immunostimulants polyI:C and CpG with consistent size and tunable charge. In a mouse tumor 
model, these polyplexes mitigated systemic markers of toxicity in comparison to free TLR 
agonists, demonstrating increased retention. TLR activation and diffusion in model tumor tissue 
were highly dependent on the TLR agonist accessibility and particle properties, which can be 
tuned by altering the ratio of GA to the TLR agonist polyanion. While GA formed a polyplex 
particle with both polyI:C and CpG, CpG polyplexes exhibited higher retention at the simulated 
injection site and enhanced TLR activation capabilities. These results demonstrate the 
importance of particle characteristics in terms of efficacy and retention ability. Particle formation 
and immobilization of immunostimulant are not the only requirements for subsequent TLR 
activation or retention; interaction strength of the polyplex plays a significant role. This work 
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displayed a novel method of delivering immunostimulants but also highlighted the design factors 
that affect the function of polyplexes. 
To conclude, the data in this dissertation demonstrates the use of polycations as delivery 
tools in cancer immunotherapy for not only increasing intracellular delivery, but also for 
increasing injection site retention through electrostatic interactions with extracellular matrix. 
These polyplexes offer a promising therapeutic approach for decreasing systemic toxicity 
generated by immunostimulants. Upon consideration of the results from both chapters, one could 
speculate that the charge density, and presence of different types of residues on the polycation 
(the differences between PLL and GA) may have a significant influence on the ability to create a 
particle, cytotoxicity level, and ability to increase TLR activation in vitro. Previous studies from 
the Berkland lab have suggested a similar hypotheses that the anionic, cationic, and hydrophobic 
amino acids of GA may aid in transfection efficiency in comparison to PLL.12 Furthermore, a 
balance of hydrophobic and positively charged domains has been seen to be important for 
penetration of cell-penetrating peptides used for intracellular delivery.13-15 In addition to the type 
of polycation, polyplex particle formation, retention ability, and TLR activation ability varied 
based on the type of immunostimulant used. In both chapters this seemed to be driven by 
different interaction strengths but could also be due to structural arrangement of the polyplex. 
Overall, the approved and safe drug, GA was a highly effective at complexing and delivering 
negatively charged immunostimulants in comparison to PLL, a polycation routinely utilized for 
delivery of nucleic acid material. In tumor studies the GA + CpG polyplexes exhibited marked 
tumor burden reduction and were able to reduce levels of systemic pro-inflammatory cytokines 
in comparison to CpG alone suggesting increased injection site retention. Efficient and safe 
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delivery of immunostimulants will be a powerful tool for cancer immunotherapy and could either 
be administered alone or in synergy with checkpoint inhibitor mAbs to increase their efficacy.  
2. Future Directions 
These studies demonstrate the encouraging potential use of polycations in local injection 
site retention for negatively charged immunostimulants which would otherwise cause systemic 
toxicity, however, there are many aspects that remain to be explored. Future studies should focus 
on optimizing the components and composition of the polyplex such that the polyplex interaction 
strength allows for efficient TLR activation, the biophysical characteristics strengthen the retention 
and intracellular delivery, and cellular toxicity is minimized. Further, a better understanding of 
GA polyplexes enhanced ability to activate TLR over PLL polyplexes may aid in design of future 
polycations for immunostimulant delivery. Finally, more in vitro and in vivo studies would be 
needed to evaluate further changes in composition but also to assess the mechanisms involved after 
local injection of polyplex.  
In both chapters, a range of ratios of polycation to immunostimulant were assessed for their 
different characteristics, ability to retain, and activate TLR. As stated in the conclusions, a larger 
ratio led to greater retention abilities but lower ratios had enhanced TLR activation. Further work 
should narrow down the ideal window of ratio that achieves a balance between retention and TLR 
activation. Other possibilities for future work in terms of the composition of the polyplex would 
be modifying the individual components to change the physical characteristics of the polyplex, 
using a different polycation, or using different immunostimulants. One significant factor in cellular 
uptake and local retention of therapy is particle size.11 In this work, mixing unmodified polycation 
and immunostimulant led to the formation of a particle (excluding PLL + polyI:C) between 40-
136
150 nm in diameter which was not tunable based on ratio. An interesting extension of this work 
could be examining chemical modifications of the individual components to see if the particle size 
can be controlled- followed by determination of optimal size for uptake and decreased diffusion 
away from injection site.  
In addition to the physical composition of the polyplex, other work may include using 
different polycations or different immunostimulants. For example, CpG comes in a few different 
classes that have different structures and slightly different in vivo effects. As discussed in chapter 
1, much research has attempted to use modified versions of CpG to increase stability and increase 
efficacy. Similarly, for this work changing the CpG class or using modified versions could alter 
the polyplex characteristics but also impact the efficacy. While the use of a safe and approved drug 
as a delivery tool is attractive, some may argue that GA is difficult to use in this context due to its 
heterogeneity. Therefore, a great future branch of this work could include the design of an ideal 
polycation. Comparing both PLL and GA as polycations for delivery led to an interesting idea to 
design a peptide for delivery that has similar characteristics to GA in terms of the balance of 
hydrophobic and positive domains.  
While the simulation of tissue retention experiments in this work provided information 
about the polyplex compared to the controls, further work could be done to improve the model. 
For example, CpG can be degraded in vivo by enzymes that cleave the DNA backbone therefore 
it would be valuable to examine the effect of the addition some of these physiological components 
to the hyaluronic acid.  Additionally, ongoing efforts in the lab are working to create a model tumor 
using cross-linked hyaluronic acid and collagen with an aim to measure diffusion of therapy. In 
animals, there are plans to measure retention in HNSCC tumors using radiolabeled polyplexes for 
the GA + CpG polyplexes. In this study, a different radiolabel would be conjugated to each 
137
component of the polyplex. This study design would be compelling for the evaluation of not only 
retention in vivo but also observing the interaction strength of polyplexes. In the case of some of 
the polyI:C polyplexes, it was hypothesized that the components were disassociating from each 
other in cell culture media or in the retention study. It would be very interesting to see after 
radiolabeling, if in vivo, the components separated and trafficked separately.  
One critical future animal study would be determination of dose and ratio. As mentioned 
in Chapter 3, there may have been some anaphylaxis reactions for animals dosed with GA, which 
highlights the importance of optimizing the dose required. In chapter 3, CpG alone had enhanced 
tumor burden reduction than the two polyplexes but showed drastically increased systemic 
cytokines. One question raised with these results was whether the differences were a result of 
increased retention in vivo or rather availability of the immunostimulant within the polyplex- 
meaning in a polyplex of sufficient interaction strength, was the dose effectively lowered? Further, 
optimization of ratio has the same justifications as mentioned previously, balancing charge and 
interaction strength for optimized retention and efficacy. To elucidate mechanisms of retention 
after injection, another in vivo study could use electron microscopy to image tumor issue after 
injection. Previous work in the lab captured images of GA aggregating into spherical particles and 
sticking to muscle tissue upon injection, thus it would be curious to observe what occurs after 
injection of particles that are formed pre-injection as in the polyplexes. Finally, future studies 
should evaluate the use of these polyplexes in synergy with established immunotherapies like 
checkpoint inhibitors. While checkpoint inhibitors have had an enormous impact on cancer 
immunotherapy, it is estimated that only 12.46% of patients are receptive to the therapy.16 Patients 
who have tumors with excluded immune cells, or ‘cold’ tumors, are much less likely to be have 
success with checkpoint inhibitors. Local administration of immunostimulants like polyI:C and 
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CpG can induce recruitment of immune cells to the tumor by activating an innate immune response 
and therefore could expand the reach of the checkpoint inhibitors.  
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